n(g),n(g')-dimethyl-l-arginine has been researched along with Hypertension in 180 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this longitudinal study (follow-up: 2 weeks-6 months), repeated measurements over time of muscle sympathetic nerve activity corrected (MSNAC), plasma levels of ADMA and symmetric dimethylarginine (SDMA), and BP and heart rate were performed in 14 patients with drug-resistant hypertension who underwent bilateral renal denervation (enrolled in 2013 and followed-up until February 2014)." | 9.20 | Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. ( Auguadro, C; D'Arrigo, G; Grassi, G; Mallamaci, F; Mancia, G; Pizzini, P; Scalise, F; Seravalle, G; Spaziani, D; Trevano, FQ; Tripepi, G; Zoccali, C, 2015) |
| "Potential role of L-arginine supplementation as a new effective strategy of improving endothelial function in patients with hypertension is recently under consideration." | 9.16 | Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citruline, L-arginine and antioxidant status. ( Ast, J; Bogdaski, P; Cielewicz, AR; Drozdowski, M; Jabecka, A; Pawlak-Lemaska, K; Pupek-Musialik, D, 2012) |
| "A total of 120 patients with hypertension were randomly divided to three groups (n = 40 each): group 1 (standard medication), group 2 (adding folic acid 5 mg/day and vitamin B(12) 500 µg twice daily) and group 3 (adding folic acid 5 mg/day and vitamin B(12) 500 µg twice daily and probucol 500 mg twice daily)." | 9.16 | [Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients]. ( Li, X; Ma, JP; Wang, CX; Wang, L; Wu, CJ; Xia, XS, 2012) |
| " A decrease in nitric oxide levels was reported in different hypertension models associated with increased concentrations of asymmetric dimethylarginine (ADMA) and homocysteine, and we recently described an increase in arginase type II expression under hypoxia." | 9.12 | Activation of arginase II by asymmetric dimethylarginine and homocysteine in hypertensive rats induced by hypoxia: a new model of nitric oxide synthesis regulation in hypertensive processes? ( López, V; Moraga, FA; Uribe, E, 2021) |
| "To investigate the relationship between serum asymmetric dimethylarginine (ADMA) and blood pressure as well as target organ damage in essential hypertension, and to evaluate the effects of enalapril and losartan on them." | 9.11 | [Changes of serum asymmetric dimethylarginine in essential hypertension before and after the treatment]. ( Chen, BM; Tao, LJ; Xiong, Y; Zhang, WR, 2005) |
| "Plasma levels of an endogenous nitric oxide (NO) synthase inhibitor, asymmetric dimethylarginine (ADMA), are elevated in chronic renal failure, hypertension, and chronic heart failure." | 9.10 | Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. ( Achan, V; Broadhead, M; Leiper, J; MacAllister, R; Malaki, M; Vallance, P; Whitley, G, 2003) |
| "Previous studies have demonstrated that the levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, are strongly associated with hypertension, diabetes, and cardiovascular diseases." | 8.12 | Effect of profilin-1 on the asymmetric dimethylarginine-induced vascular lesion-associated hypertension. ( Chen, MF; Cheng, JF; Li, YJ; Ni, GH; Xie, QY; Yang, TL, 2022) |
| "Asymmetric dimethylarginine (ADMA) is considered an independent cardiovascular risk factor (cvRF) and thus represents a potential new biomarker for retinal vein occlusion (RVO)." | 8.02 | [Asymmetric dimethylarginine (ADMA) in retinal vein occlusion-Results from the Gutenberg RVO study]. ( Binder, H; Closs, EI; Gericke, A; Habermeier, A; Pfeiffer, N; Ponto, KA; Rosner, AK; Scharrer, I, 2021) |
| "Resveratrol, a phytochemical, has shown antioxidant properties and potential benefits in hypertension." | 8.02 | Maternal resveratrol therapy protected adult rat offspring against hypertension programmed by combined exposures to asymmetric dimethylarginine and trimethylamine-N-oxide. ( Chan, JYH; Chang-Chien, GP; Hou, CY; Hsu, CN; Lee, CT; Lin, S; Tain, YL, 2021) |
| "Asymmetric dimethylarginine (ADMA) is a robust marker of endothelial dysfunction in patients with essential hypertension." | 7.88 | Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes. ( Anyfanti, P; Dipla, K; Douma, S; Gavriilaki, E; Gkaliagkousi, E; Koletsos, N; Lazaridis, A; Nikolaidou, B; Triantafyllou, A; Vamvakis, A, 2018) |
| "The study aimed to investigate the protective effect of tanshinone IIA against cardiac hypertrophy in spontaneously hypertensive rats (SHRs) through the Cys-C/Wnt signaling pathway." | 7.85 | Protective effect of tanshinone IIA against cardiac hypertrophy in spontaneously hypertensive rats through inhibiting the Cys-C/Wnt signaling pathway. ( Chen, HW; Feng, J; Pi, LJ; Wang, J; Zhan, DQ, 2017) |
| " The aim of this study was to evaluate early change in BP and its relation to insulin resistance (IR) and asymmetric dimethylarginine (ADMA)." | 7.83 | Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine. ( Chiarelli, F; Chiavaroli, V; de Giorgis, T; Giannini, C; Marcovecchio, ML; Mohn, A, 2016) |
| " Asymmetrical dimethylarginine (ADMA), the most potent endogenous NO synthase inhibitor, is emerging as an important cardiovascular risk factor in patients with arterial hypertension and LVH, and dimethylarginine dimethylaminohydrolase (DDAH) is the mechanism that most frequently leads to accumulation of ADMA (plasma ADMA is cleared in small part by renal excretion, although the bulk of ADMA is degraded by DDAH)." | 7.83 | Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol? ( Delgado-Baeza, E; Quintana-Villamandos, B, 2016) |
| " We investigated the relationship between arterial stiffness parameters and asymmetric dimethylarginine (ADMA; a marker of ED), in newly diagnosed patients with hypertension (n = 101; 61 females)." | 7.81 | Asymmetric dimethylarginine and augmentation index in newly diagnosed patients with hypertension. ( Akhan, M; Altun, B; Arslan, E; Ay, SA; Balta, Ş; Bulucu, F; Cakar, M; Demirbaş, Ş; Demirkol, S; Karaman, M; Kurt, Ö; Sağlam, K; Sarlak, H; Yaman, H, 2015) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is involved in hypertension." | 7.81 | Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction. ( Hsu, CN; Huang, LT; Lee, CT; Tain, YL, 2015) |
| "This study was to assess the relationship between asymmetric dimethylarginine (ADMA) and carotid atherosclerosis in patients with essential hypertension." | 7.81 | Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension. ( Wang, X; Xia, W; Xu, L; Xu, W; Yao, Y, 2015) |
| "Elevated asymmetric dimethylarginine (ADMA) levels and nitric oxide (NO) deficiency are associated with the development of hypertension." | 7.80 | Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats. ( Hsu, CN; Huang, LT; Kuo, HC; Tain, YL; Tsai, CM, 2014) |
| " Asymmetric dimethylarginine (ADMA) is increased in diabetes mellitus, kidney disease, and hypertension." | 7.79 | Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers. ( Hsu, CN; Huang, LT; Lee, CT; Lee, WC; Lin, CY; Tain, YL, 2013) |
| "Asymmetric dimethylarginine (ADMA) reduces nitric oxide (NO), thus causing hypertension." | 7.79 | N-acetylcysteine prevents hypertension via regulation of the ADMA-DDAH pathway in young spontaneously hypertensive rats. ( Fan, NC; Hsu, CN; Huang, LT; Tain, YL; Tsai, CM, 2013) |
| "Plasma concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) increase already in the early stages of renal insufficiency." | 7.78 | Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency. ( Bakker, JA; Bierau, J; De Leeuw, PW; Houben, AJ; Kroon, AA; Ronden, RA; Stehouwer, CD; Teerlink, T, 2012) |
| "To investigate the relationship between periodontal disease indexes (PDI) and endothelial dysfunction by means of asymmetric dimethyl-arginine (ADMA) in conditions of both increased and decreased systemic inflammation in the setting of hypertension." | 7.76 | The conjoint detrimental effect of chronic periodontal disease and systemic inflammation on asymmetric dimethyl-arginine in untreated hypertensive subjects. ( Kasiakogias, A; Mostratou, E; Silvestros, S; Soldatos, N; Stefanadi, E; Stefanadis, C; Syrseloudis, D; Thomopoulos, C; Tsioufis, C, 2010) |
| "Plasma levels of AEA, CGRP, asymmetric dimethylarginine (ADMA) and nitric oxide in patients with essential hypertension, spontaneously hypertensive rats (SHRs) and 2 kidney 1 clip hypertensive rats and the CGRP mRNA expression in dorsal root ganglion of rats were measured." | 7.75 | Role of anandamide transporter in regulating calcitonin gene-related peptide production and blood pressure in hypertension. ( Chen, BM; Deng, HW; Hu, CP; Li, D; Li, XH; Li, YJ; Peng, J; Yuan, Q; Zhang, YS, 2009) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase (NOS), and endothelial dysfunction is related to the elevation of ADMA level in hypertension." | 7.74 | Reduction of NO- and EDHF-mediated vasodilatation in hypertension: role of asymmetric dimethylarginine. ( Jiang, DJ; Li, D; Li, J; Li, YJ; Liu, H; Tan, B; Zhou, Z, 2007) |
| "The goal of this study was to examine the relationship between plasma asymmetric dimethylarginine (ADMA) level and hyperemic myocardial blood flow (MBF) in subjects with borderline hypertension (BHT) and familial hypercholesterolemia (FH)." | 7.71 | Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. ( Knuuti, J; Laakso, J; Laaksonen, R; Laine, H; Päivä, H; Raitakari, OT, 2002) |
| " The present experiments were designed to investigate the role of asymmetrical NG,NG-dimethyl-L-arginine (ADMA) in causing hypertension associated with the focal and segmental glomerulosclerosis (FSGS) produced by a single bolus of puromycin aminonucleoside (PAN) and successive injection of protamine for 7 days in rats which had undergone unilateral nephrectomy." | 7.70 | Endogenous asymmetrical dimethylarginine and hypertension associated with puromycin nephrosis in the rat. ( Azuma, H; Hamasaki, H; Ishizaka, K; Masuda, H; Matsubara, O; Sato, J; Tamaoki, S, 1998) |
| " A potential reason for this is reduced nitric oxide bioavailability in African Americans, resulting in increased prevalence of factors that contribute to ventricular dysfunction." | 6.77 | Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study. ( Bhaheetharan, S; Ferdinand, KC; Haque, T; Harris, J; Khan, BV; Merchant, N; Rahman, ST; Umar, K; Wahi, J, 2012) |
| "Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications." | 6.47 | L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes. ( Dain, A; Das, UN; Eynard, AR; Repossi, G, 2011) |
| "Global L-arginine bioavailability was diminished, whereas plasma arginase activity, ADMA, and SDMA levels were elevated, in patients with RA compared with healthy control subjects." | 5.48 | Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. ( Chandrasekharan, UM; Elaine Husni, M; Hazen, SL; Wang, S; Wang, Z; Wilson Tang, WH; Wu, Y, 2018) |
| "Suramin treatment exerted negligible effect on the RAS pathway in the adult male offspring kidneys." | 5.43 | N-Acetylcysteine Prevents Programmed Hypertension in Male Rat Offspring Born to Suramin-Treated Mothers. ( Hsu, CN; Lee, CT; Lin, YJ; Tain, YL; Tsai, CC, 2016) |
| "Although, several drugs are used to treat hypertension, the success of the antihypertensive therapy is limited." | 5.42 | Resveratrol affects histone 3 lysine 27 methylation of vessels and blood biomarkers in DOCA salt-induced hypertension. ( Akcali, KC; Ayaloglu-Butun, F; Demirel-Yilmaz, E; Han, S; Uludag, MO; Usanmaz, SE, 2015) |
| " Both treatments restored NO bioavailability and reduced oxidative stress in SHR kidneys." | 5.40 | Two different approaches to restore renal nitric oxide and prevent hypertension in young spontaneously hypertensive rats: l-citrulline and nitrate. ( Chien, SJ; Huang, CF; Huang, LT; Kuo, HC; Lin, KM; Lin, YJ; Tain, YL, 2014) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous modulator of endothelial function and oxidative stress, and increased levels of this molecule have been reported in some metabolic disorders and cardiovascular diseases." | 5.37 | Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome. ( Collin, B; Cottin, Y; Duvillard, L; Goirand, F; Guilland, JC; Korandji, C; Lauzier, B; Moreau, D; Rochette, L; Sicard, P; Vergely, C; Zeller, M, 2011) |
| " Early aliskiren treatment mitigates increases in ADMA, restores l-Arg-to-ADMA ratios, enhances neuronal NOS-α, prevents decreased nNOS-β levels in the kidney-which might restore NO bioavailability and contribute to the decrease of blood pressure in young SHRs." | 5.37 | Aliskiren prevents hypertension and reduces asymmetric dimethylarginine in young spontaneously hypertensive rats. ( Hsu, CN; Huang, LT; Lau, YT; Lin, CY; Tain, YL, 2011) |
| "Melatonin-treated rats received 0." | 5.36 | Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. ( Huang, LT; Lau, YT; Lin, CY; Lin, IC; Tain, YL, 2010) |
| "This was a double-blinded, randomized, placebo-controlled, mechanistic study, comparing microvascular effects of the DPP-IV inhibitor linagliptin with placebo in nondiabetic individuals with a history of arterial hypertension." | 5.22 | Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients. ( Diessel, S; Forst, T; Jahnke, J; Kapitza, C; Michelson, G, 2016) |
| "In this longitudinal study (follow-up: 2 weeks-6 months), repeated measurements over time of muscle sympathetic nerve activity corrected (MSNAC), plasma levels of ADMA and symmetric dimethylarginine (SDMA), and BP and heart rate were performed in 14 patients with drug-resistant hypertension who underwent bilateral renal denervation (enrolled in 2013 and followed-up until February 2014)." | 5.20 | Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. ( Auguadro, C; D'Arrigo, G; Grassi, G; Mallamaci, F; Mancia, G; Pizzini, P; Scalise, F; Seravalle, G; Spaziani, D; Trevano, FQ; Tripepi, G; Zoccali, C, 2015) |
| "The findings demonstrate that nisoldipine and olmesartan both improve FMD in patients with essential hypertension." | 5.16 | Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients. ( He, WY; Lv, QZ; Wei, D, 2012) |
| "A prospective 12-week pilot study of carvedilol titrated to 50 mg twice daily was performed among 25 hemodialysis participants with intradialytic hypertension." | 5.16 | Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. ( Inrig, JK; Kim, C; Povsic, TJ; Toto, R; Van Buren, P; Vongpatanasin, W, 2012) |
| "Potential role of L-arginine supplementation as a new effective strategy of improving endothelial function in patients with hypertension is recently under consideration." | 5.16 | Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citruline, L-arginine and antioxidant status. ( Ast, J; Bogdaski, P; Cielewicz, AR; Drozdowski, M; Jabecka, A; Pawlak-Lemaska, K; Pupek-Musialik, D, 2012) |
| "A total of 120 patients with hypertension were randomly divided to three groups (n = 40 each): group 1 (standard medication), group 2 (adding folic acid 5 mg/day and vitamin B(12) 500 µg twice daily) and group 3 (adding folic acid 5 mg/day and vitamin B(12) 500 µg twice daily and probucol 500 mg twice daily)." | 5.16 | [Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients]. ( Li, X; Ma, JP; Wang, CX; Wang, L; Wu, CJ; Xia, XS, 2012) |
| "In patients with T2D, hypertension and overt nephropathy, the renoprotection afforded by telmisartan and valsartan appears similar, and the study was unable to show any effect beyond that due to blood pressure control." | 5.13 | Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. ( Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C, 2008) |
| " A decrease in nitric oxide levels was reported in different hypertension models associated with increased concentrations of asymmetric dimethylarginine (ADMA) and homocysteine, and we recently described an increase in arginase type II expression under hypoxia." | 5.12 | Activation of arginase II by asymmetric dimethylarginine and homocysteine in hypertensive rats induced by hypoxia: a new model of nitric oxide synthesis regulation in hypertensive processes? ( López, V; Moraga, FA; Uribe, E, 2021) |
| "The sulfhydryl ACE inhibitor zofenopril reduces oxidative stress and improves the NO pathway in patients with essential hypertension." | 5.11 | Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. ( Condorelli, M; de Nigris, F; Ignarro, LJ; Liguori, A; Napoli, C; Pignalosa, O; Sica, V, 2004) |
| "To investigate the relationship between serum asymmetric dimethylarginine (ADMA) and blood pressure as well as target organ damage in essential hypertension, and to evaluate the effects of enalapril and losartan on them." | 5.11 | [Changes of serum asymmetric dimethylarginine in essential hypertension before and after the treatment]. ( Chen, BM; Tao, LJ; Xiong, Y; Zhang, WR, 2005) |
| "Patients with essential hypertension (n = 24) were administered a low-salt diet (2 g NaCl/day), a high-salt diet (20-23 g) and then a low-salt diet for 7 days, and plasma levels of nitrate and nitrite (NOx) and asymmetric dimethylarginine (ADMA) were examined." | 5.10 | Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease. ( Fujiwara, N; Nakamura, M; Okumura, K; Osanai, T; Osawa, H; Saitoh, M; Sasaki, S; Tomita, H; Yamabe, H, 2002) |
| "Plasma levels of an endogenous nitric oxide (NO) synthase inhibitor, asymmetric dimethylarginine (ADMA), are elevated in chronic renal failure, hypertension, and chronic heart failure." | 5.10 | Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. ( Achan, V; Broadhead, M; Leiper, J; MacAllister, R; Malaki, M; Vallance, P; Whitley, G, 2003) |
| "Nutritional factors such as magnesium, folic acid, vitamins B12 and B6, L-arginine, and polyunsaturated fatty acids (PUFAs) appear to be significantly beneficial for patients with coronary artery disease (CAD), and in the prevention and arresting the progression of HF and cardiac arrhythmias." | 4.91 | Nutritional factors in the prevention and management of coronary artery disease and heart failure. ( Das, UN, 2015) |
| " Thus, together with classic risk factors such as hypertension, dyslipidemia and diabetes, other situations such as microinflammation, increased concentration of asymmetrical dimethyl-L-arginine, disturbed phosphate metabolism and anemia may represent important risk factors for accelerated atherosclerosis in dialyzed patients." | 4.82 | Atherosclerosis in dialyzed patients. ( Ritz, E, 2004) |
| "Previous studies have demonstrated that the levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, are strongly associated with hypertension, diabetes, and cardiovascular diseases." | 4.12 | Effect of profilin-1 on the asymmetric dimethylarginine-induced vascular lesion-associated hypertension. ( Chen, MF; Cheng, JF; Li, YJ; Ni, GH; Xie, QY; Yang, TL, 2022) |
| "Asymmetric dimethylarginine (ADMA) is considered an independent cardiovascular risk factor (cvRF) and thus represents a potential new biomarker for retinal vein occlusion (RVO)." | 4.02 | [Asymmetric dimethylarginine (ADMA) in retinal vein occlusion-Results from the Gutenberg RVO study]. ( Binder, H; Closs, EI; Gericke, A; Habermeier, A; Pfeiffer, N; Ponto, KA; Rosner, AK; Scharrer, I, 2021) |
| "The study included 53 men, 20 with hypertension (HTN), 18 with HTN and related diseases, 15 healthy controls Apart from general testing (BMI, biochemical analysis, SBP, DBP), we used the Griess reaction to assess the total amount of nitric oxide (NO), and used ELISA to verify the concentrations of malondialdehyde (MDA), nitrotyrosine (NT), asymmetric dimethylarginine (ADMA), tumor necrosis factor-alpha (TNF-α), monocyte chemotactic protein 1 (MCP-1), and myeloperoxidase (MPO)." | 4.02 | Profile of new vascular damage biomarkers in middle-aged men with arterial hypertension. ( Charkiewicz, AE; Garley, M; Jabłońska, E; Maślach, D; Nowak, K; Omeljaniuk, WJ; Ratajczak-Wrona, W, 2021) |
| "Resveratrol, a phytochemical, has shown antioxidant properties and potential benefits in hypertension." | 4.02 | Maternal resveratrol therapy protected adult rat offspring against hypertension programmed by combined exposures to asymmetric dimethylarginine and trimethylamine-N-oxide. ( Chan, JYH; Chang-Chien, GP; Hou, CY; Hsu, CN; Lee, CT; Lin, S; Tain, YL, 2021) |
| " Asymmetric dimethyl arginine (ADMA) levels promote the development of endothelial dysfunction and atherosclerosis-related diseases such as hypertension, acute coronary syndrome, congestive heart failure, and peripheral vascular diseases." | 3.91 | Assessment of Endothelial Dysfunction with Methylated Arginines and L-arginine in Cadmium-Exposed People: a Pilot Study. ( Cetintepe, SP; Deniz, S; Gunduzoz, M; Iritas, SB; Oztan, O; Tekin, G; Turksoy, VA; Tutkun, L; Unlu, A, 2019) |
| "Asymmetric dimethylarginine (ADMA) is a robust marker of endothelial dysfunction in patients with essential hypertension." | 3.88 | Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes. ( Anyfanti, P; Dipla, K; Douma, S; Gavriilaki, E; Gkaliagkousi, E; Koletsos, N; Lazaridis, A; Nikolaidou, B; Triantafyllou, A; Vamvakis, A, 2018) |
| "The study aimed to investigate the protective effect of tanshinone IIA against cardiac hypertrophy in spontaneously hypertensive rats (SHRs) through the Cys-C/Wnt signaling pathway." | 3.85 | Protective effect of tanshinone IIA against cardiac hypertrophy in spontaneously hypertensive rats through inhibiting the Cys-C/Wnt signaling pathway. ( Chen, HW; Feng, J; Pi, LJ; Wang, J; Zhan, DQ, 2017) |
| " The aim of this study was to evaluate early change in BP and its relation to insulin resistance (IR) and asymmetric dimethylarginine (ADMA)." | 3.83 | Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine. ( Chiarelli, F; Chiavaroli, V; de Giorgis, T; Giannini, C; Marcovecchio, ML; Mohn, A, 2016) |
| "The characteristics of the Asian hypertensive patients with diastolic hypertension can present a favourable metabolic response to the short-term hydrochlorothiazide treatment." | 3.83 | Hypertension subtypes modify metabolic response to thiazide diuretics. ( Chen, JW; Huang, CC; Huang, PH; Leu, HB; Lin, LY; Lin, SJ; Wu, TC, 2016) |
| " Asymmetrical dimethylarginine (ADMA), the most potent endogenous NO synthase inhibitor, is emerging as an important cardiovascular risk factor in patients with arterial hypertension and LVH, and dimethylarginine dimethylaminohydrolase (DDAH) is the mechanism that most frequently leads to accumulation of ADMA (plasma ADMA is cleared in small part by renal excretion, although the bulk of ADMA is degraded by DDAH)." | 3.83 | Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol? ( Delgado-Baeza, E; Quintana-Villamandos, B, 2016) |
| "Our preclinical study demonstrated that esmolol produces early regression of left ventricular hypertrophy in arterial hypertension." | 3.83 | Early regression of coronary artery remodeling with esmolol and DDAH/ADMA pathway in hypertensive rats. ( Arnalich-Montiel, A; Arribas, S; Böger, RH; Delgado-Baeza, E; Delgado-Martos, MJ; Fernández-Criado, C; González, MC; Lüneburg, N; Quintana-Villamandos, B, 2016) |
| "Asymmetric dimethylarginine (ADMA), the endogenous inhibitor of nitric oxide synthase, contributes to endothelial dysfunction and subsequent cardiovascular events including hypertension." | 3.83 | Vascular peroxidase 1 up regulation by angiotensin II attenuates nitric oxide production through increasing asymmetrical dimethylarginine in HUVECs. ( Chen, L; Cheng, G; Huang, X; Peng, H; Shi, R; Yang, T; Yu, Z; Zhang, G, 2016) |
| " We investigated the relationship between arterial stiffness parameters and asymmetric dimethylarginine (ADMA; a marker of ED), in newly diagnosed patients with hypertension (n = 101; 61 females)." | 3.81 | Asymmetric dimethylarginine and augmentation index in newly diagnosed patients with hypertension. ( Akhan, M; Altun, B; Arslan, E; Ay, SA; Balta, Ş; Bulucu, F; Cakar, M; Demirbaş, Ş; Demirkol, S; Karaman, M; Kurt, Ö; Sağlam, K; Sarlak, H; Yaman, H, 2015) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is involved in hypertension." | 3.81 | Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction. ( Hsu, CN; Huang, LT; Lee, CT; Tain, YL, 2015) |
| "This study was to assess the relationship between asymmetric dimethylarginine (ADMA) and carotid atherosclerosis in patients with essential hypertension." | 3.81 | Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension. ( Wang, X; Xia, W; Xu, L; Xu, W; Yao, Y, 2015) |
| " Melatonin therapy prevented L-NAME-exacerbated hypertension and nephrosclerosis in young SHRs." | 3.80 | Renoprotective effects of melatonin in young spontaneously hypertensive rats with L-NAME. ( Cheng, MC; Huang, LT; Tain, YL; Wu, TH, 2014) |
| "Elevated asymmetric dimethylarginine (ADMA) levels and nitric oxide (NO) deficiency are associated with the development of hypertension." | 3.80 | Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats. ( Hsu, CN; Huang, LT; Kuo, HC; Tain, YL; Tsai, CM, 2014) |
| " Asymmetric dimethylarginine (ADMA) is increased in diabetes mellitus, kidney disease, and hypertension." | 3.79 | Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers. ( Hsu, CN; Huang, LT; Lee, CT; Lee, WC; Lin, CY; Tain, YL, 2013) |
| "Asymmetric dimethylarginine (ADMA) reduces nitric oxide (NO), thus causing hypertension." | 3.79 | N-acetylcysteine prevents hypertension via regulation of the ADMA-DDAH pathway in young spontaneously hypertensive rats. ( Fan, NC; Hsu, CN; Huang, LT; Tain, YL; Tsai, CM, 2013) |
| "Both NADPH oxidase-derived reactive oxygen species (ROS) and asymmetric dimethylarginine (ADMA) are increased in hypertension." | 3.78 | Apocynin attenuates oxidative stress and hypertension in young spontaneously hypertensive rats independent of ADMA/NO pathway. ( Hsu, CN; Huang, LT; Lau, YT; Tain, YL, 2012) |
| " Hypertension may be induced by inadequate release of L-arginine-derived nitric oxide impairing vascular tone regulation." | 3.78 | Ethnicity-specific differences in L-arginine status in South African men. ( Anderssohn, M; Böger, RH; Fourie, CM; Glyn, MC; Huisman, HW; Lüneburg, N; Malan, L; Malan, NT; Mels, CM; Schutte, AE; Schutte, R; Smith, W; Van Rooyen, JM, 2012) |
| "Plasma concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) increase already in the early stages of renal insufficiency." | 3.78 | Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency. ( Bakker, JA; Bierau, J; De Leeuw, PW; Houben, AJ; Kroon, AA; Ronden, RA; Stehouwer, CD; Teerlink, T, 2012) |
| " Patients with metabolic syndrome (MS) had lower activity of gluthatione peroxidase, higher asymmetric dimethyloarginine (ADMA) and oxidized LDL cholesterol (oxyLDL) in comparison to patients without MS." | 3.78 | Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy. ( Janas, R; Litwin, M; Niemirska, A; Płudowski, P; Skorupa, E; Sladowska-Kozłowska, J; Wawer, ZT; Wierzbicka, A, 2012) |
| "This study was designed to explore the role of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in platelet aggregation in hypertension and its possible mechanisms." | 3.77 | Increased plasma level of asymmetric dimethylarginine in hypertensive rats facilitates platelet aggregation: role of plasma tissue factor. ( Chen, QQ; Chen, X; Guo, R; Hu, CP; Li, D, 2011) |
| " We found that mild hypertension, increased plasma levels of creatinine, inorganic phosphate, asymmetric dimethylarginine (ADMA), and parathyroid hormone (PTH) were observed in the present SNx rats without LVH." | 3.77 | Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats. ( Aizawa, K; Ishizuka, N; Iwabuchi, S; Kitamura, H; Moriguchi, Y; Nishimura, T; Serizawa, K; Tashiro, Y; Yogo, K; Yorozu, K, 2011) |
| "To investigate the relationship between periodontal disease indexes (PDI) and endothelial dysfunction by means of asymmetric dimethyl-arginine (ADMA) in conditions of both increased and decreased systemic inflammation in the setting of hypertension." | 3.76 | The conjoint detrimental effect of chronic periodontal disease and systemic inflammation on asymmetric dimethyl-arginine in untreated hypertensive subjects. ( Kasiakogias, A; Mostratou, E; Silvestros, S; Soldatos, N; Stefanadi, E; Stefanadis, C; Syrseloudis, D; Thomopoulos, C; Tsioufis, C, 2010) |
| "Elevated blood concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric-oxide (NO) synthase, are found in association with diabetes, hypertension, congestive heart failure, and atherosclerosis." | 3.76 | Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. ( Lentz, SR; Murry, DJ; Rodionov, RN; Stevens, JW; Vaulman, SF, 2010) |
| "Asymmetric dimethylarginine (ADMA) and subclinical inflammation are associated with atherosclerosis progression, whereas microalbuminuria is an established index of hypertensive organ damage." | 3.76 | ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. ( Andrikou, E; Dimitriadis, K; Mihas, C; Miliou, A; Papademetriou, V; Stefanadi, E; Stefanadis, C; Thomopoulos, C; Tsiachris, D; Tsioufis, C, 2010) |
| "Plasma levels of AEA, CGRP, asymmetric dimethylarginine (ADMA) and nitric oxide in patients with essential hypertension, spontaneously hypertensive rats (SHRs) and 2 kidney 1 clip hypertensive rats and the CGRP mRNA expression in dorsal root ganglion of rats were measured." | 3.75 | Role of anandamide transporter in regulating calcitonin gene-related peptide production and blood pressure in hypertension. ( Chen, BM; Deng, HW; Hu, CP; Li, D; Li, XH; Li, YJ; Peng, J; Yuan, Q; Zhang, YS, 2009) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase (NOS), and endothelial dysfunction is related to the elevation of ADMA level in hypertension." | 3.74 | Reduction of NO- and EDHF-mediated vasodilatation in hypertension: role of asymmetric dimethylarginine. ( Jiang, DJ; Li, D; Li, J; Li, YJ; Liu, H; Tan, B; Zhou, Z, 2007) |
| " We assessed blood concentrations of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) as well as renal hemodynamics, comparing young (n=24, 13 men, 25+/-1 years) and elderly (n=24, 13 men, 69+/-2 years) healthy subjects and elderly subjects with essential hypertension (n=24, 13 men, 70+/-2 years)." | 3.72 | Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. ( Bode-Böger, SM; Fliser, D; Frölich, JC; Haller, H; Kielstein, JT; Ritz, E, 2003) |
| " We hypothesized that changes in serum asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, and concomitant insulin resistance may be underlying factors connecting the two pathologic alterations." | 3.72 | Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. ( Fujii, H; Hiuge, A; Horio, T; Kamide, K; Kawano, Y; Nakatani, S; Ogihara, T; Rakugi, H; Takiuchi, S, 2004) |
| "The goal of this study was to examine the relationship between plasma asymmetric dimethylarginine (ADMA) level and hyperemic myocardial blood flow (MBF) in subjects with borderline hypertension (BHT) and familial hypercholesterolemia (FH)." | 3.71 | Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. ( Knuuti, J; Laakso, J; Laaksonen, R; Laine, H; Päivä, H; Raitakari, OT, 2002) |
| "Rosiglitazone (4 mg/d for 4 weeks and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent, was given to 7 insulin-resistant subjects with hypertension." | 3.71 | Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. ( Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS, 2002) |
| " The present experiments were designed to investigate the role of asymmetrical NG,NG-dimethyl-L-arginine (ADMA) in causing hypertension associated with the focal and segmental glomerulosclerosis (FSGS) produced by a single bolus of puromycin aminonucleoside (PAN) and successive injection of protamine for 7 days in rats which had undergone unilateral nephrectomy." | 3.70 | Endogenous asymmetrical dimethylarginine and hypertension associated with puromycin nephrosis in the rat. ( Azuma, H; Hamasaki, H; Ishizaka, K; Masuda, H; Matsubara, O; Sato, J; Tamaoki, S, 1998) |
| "To establish the role played by the circulating nitric oxide synthase inhibitors N(G)-monomethyl-L-arginine (L-NMMA), asymmetrical dimethyl arginine (ADMA) and symmetric dimethyl arginine (SDMA) and its association with hypertension of children and adolescents." | 3.69 | Nitric oxide synthase inhibitors and hypertension in children and adolescents. ( Dillon, MJ; Frend, A; Goonasekera, CD; Rees, DD; Shah, V; Woolard, P, 1997) |
| " A potential reason for this is reduced nitric oxide bioavailability in African Americans, resulting in increased prevalence of factors that contribute to ventricular dysfunction." | 2.77 | Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study. ( Bhaheetharan, S; Ferdinand, KC; Haque, T; Harris, J; Khan, BV; Merchant, N; Rahman, ST; Umar, K; Wahi, J, 2012) |
| " However, poor polyphenol bioavailability and extensive metabolization restrict their applicability." | 2.72 | Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases. ( Baião, DDS; da Silva, DVT; Paschoalin, VMF; Trindade, LR, 2021) |
| "Hypertension is the most common disease affecting humans and imparts a significant cardiovascular and renal risk to patients." | 2.55 | Novel Pathophysiological Mechanisms in Hypertension. ( Hsu, R; Lawless, S; Lee, A; Samson, R; Sander, G, 2017) |
| "Both hypertension and type 2 diabetes mellitus are common and there are no reliable markers either to predict their development or complications." | 2.47 | L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes. ( Dain, A; Das, UN; Eynard, AR; Repossi, G, 2011) |
| " Reactive oxygen species (ROS) may directly alter vascular function or cause changes in vascular tone by several mechanisms including altered nitric oxide (NO) bioavailability or signaling." | 2.47 | Oxidative stress and endothelial dysfunction in hypertension. ( Gori, T; Münzel, T; Schulz, E, 2011) |
| " Potential mechanisms underlying impaired endothelial function and decreased bioavailability of nitric oxide under these clinical conditions are discussed." | 2.42 | Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. ( John, S; Schmieder, RE, 2003) |
| "In patients with cardiac diseases, c(SDMA) was additionally increased only in the CRF group." | 2.42 | Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. ( Busch, M; Fleck, C; Karge, E; Schweitzer, F; Stein, G, 2003) |
| "Glaucoma is reportedly associated with asymmetric dimethylarginine (ADMA) and circadian blood pressure (BP) variability, including night-time SBP." | 1.91 | Circadian blood pressure variability and asymmetric dimethylarginine in patients with glaucoma: cross-sectional study of The LIGHT cohort. ( Jimura, H; Miyata, K; Obayashi, K; Ogata, N; Saeki, K; Yoshikawa, T, 2023) |
| "Global L-arginine bioavailability was diminished, whereas plasma arginase activity, ADMA, and SDMA levels were elevated, in patients with RA compared with healthy control subjects." | 1.48 | Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. ( Chandrasekharan, UM; Elaine Husni, M; Hazen, SL; Wang, S; Wang, Z; Wilson Tang, WH; Wu, Y, 2018) |
| "Suramin treatment exerted negligible effect on the RAS pathway in the adult male offspring kidneys." | 1.43 | N-Acetylcysteine Prevents Programmed Hypertension in Male Rat Offspring Born to Suramin-Treated Mothers. ( Hsu, CN; Lee, CT; Lin, YJ; Tain, YL; Tsai, CC, 2016) |
| "Although, several drugs are used to treat hypertension, the success of the antihypertensive therapy is limited." | 1.42 | Resveratrol affects histone 3 lysine 27 methylation of vessels and blood biomarkers in DOCA salt-induced hypertension. ( Akcali, KC; Ayaloglu-Butun, F; Demirel-Yilmaz, E; Han, S; Uludag, MO; Usanmaz, SE, 2015) |
| " Both treatments restored NO bioavailability and reduced oxidative stress in SHR kidneys." | 1.40 | Two different approaches to restore renal nitric oxide and prevent hypertension in young spontaneously hypertensive rats: l-citrulline and nitrate. ( Chien, SJ; Huang, CF; Huang, LT; Kuo, HC; Lin, KM; Lin, YJ; Tain, YL, 2014) |
| "Insulin sensitivity was impaired only in T2DM." | 1.39 | Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo. ( Artusi, C; Cecchet, D; Millioni, R; Plebani, M; Puricelli, L; Tessari, P; Vedovato, M; Vettore, M, 2013) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous modulator of endothelial function and oxidative stress, and increased levels of this molecule have been reported in some metabolic disorders and cardiovascular diseases." | 1.37 | Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome. ( Collin, B; Cottin, Y; Duvillard, L; Goirand, F; Guilland, JC; Korandji, C; Lauzier, B; Moreau, D; Rochette, L; Sicard, P; Vergely, C; Zeller, M, 2011) |
| " Early aliskiren treatment mitigates increases in ADMA, restores l-Arg-to-ADMA ratios, enhances neuronal NOS-α, prevents decreased nNOS-β levels in the kidney-which might restore NO bioavailability and contribute to the decrease of blood pressure in young SHRs." | 1.37 | Aliskiren prevents hypertension and reduces asymmetric dimethylarginine in young spontaneously hypertensive rats. ( Hsu, CN; Huang, LT; Lau, YT; Lin, CY; Tain, YL, 2011) |
| "Melatonin-treated rats received 0." | 1.36 | Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. ( Huang, LT; Lau, YT; Lin, CY; Lin, IC; Tain, YL, 2010) |
| "Data concerning ADMA level in type 1 diabetes (DM1) are controversial." | 1.36 | [Asymmetric dimethylarginine (ADMA) in children with diabetes type 1]. ( Bossowski, A; Florys, B; Głowińska-Olszewska, B; Jabłońska, J; Luczyński, W; Otocka, A, 2010) |
| "Elevated plasma ADMA was confirmed in ESRD and HTN populations while basal WBSUP ADMA was significantly higher in ESRD subjects than controls (P = 0." | 1.35 | Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. ( Billecke, SS; D'Alecy, LG; Gadegbeku, CA; Jamerson, KA; Perlman, RL; Platel, R; Whitesall, SE, 2009) |
| " L-arginine is independently associated with abnormal pulsatile (but not resistive) arterial hemodynamic indices, which may reflect abnormal L-arginine transport, leading to decreased intracellular bioavailability for NO synthesis." | 1.35 | Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study. ( Bralley, JA; Chirinos, JA; Chirinos-Pacheco, J; Corrales-Medina, F; Cuba-Bustinza, C; David, R; Medina-Lezama, J; Muñoz-Atahualpa, E; Zea-Díaz, H, 2008) |
| "Telmisartan is an angiotensin II receptor blocker (ARB) and also an activator of peroxisome proliferator-activated receptor-gamma (PPAR-gamma)." | 1.35 | Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. ( Bando, S; Ito, S; Nakaya, Y; Ono, Y; Sata, M; Soeki, T, 2009) |
| " Blood pressure and renal excretion were measured in adulthood, under different sodium conditions, and before and after chronic administration of either N(G)-nitro-l-arginine methyl ester (l-NAME) or l-arginine." | 1.35 | Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals. ( Brown, RD; Carlström, M; Edlund, J; Larsson, E; Palm, F; Persson, AE; Sällström, J; Teerlink, T; Wåhlin, N, 2008) |
| "Treatment with losartan (30 mg/kg) for 14 days significantly lowered blood pressure, elevated the plasma level of NO, and decreased the plasma concentration of ADMA in SHR." | 1.34 | Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. ( Deng, HW; Jiang, DJ; Li, D; Li, NS; Li, YJ; Luo, D; Wang, S; Xia, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (2.78) | 18.2507 |
| 2000's | 60 (33.33) | 29.6817 |
| 2010's | 103 (57.22) | 24.3611 |
| 2020's | 12 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ni, GH | 1 |
| Cheng, JF | 1 |
| Li, YJ | 4 |
| Xie, QY | 1 |
| Yang, TL | 2 |
| Chen, MF | 1 |
| Szlęzak, D | 1 |
| Ufnal, M | 1 |
| Drapała, A | 1 |
| Samborowska, E | 1 |
| Wróbel, M | 1 |
| Yoshikawa, T | 1 |
| Obayashi, K | 2 |
| Miyata, K | 1 |
| Jimura, H | 1 |
| Saeki, K | 2 |
| Ogata, N | 1 |
| Tutkun, L | 1 |
| Gunduzoz, M | 1 |
| Turksoy, VA | 1 |
| Deniz, S | 1 |
| Oztan, O | 1 |
| Cetintepe, SP | 1 |
| Iritas, SB | 1 |
| Tekin, G | 1 |
| Unlu, A | 4 |
| Vamvakis, A | 2 |
| Gkaliagkousi, E | 2 |
| Lazaridis, A | 2 |
| Grammatikopoulou, MG | 1 |
| Triantafyllou, A | 2 |
| Nikolaidou, B | 2 |
| Koletsos, N | 2 |
| Anyfanti, P | 2 |
| Tzimos, C | 1 |
| Zebekakis, P | 1 |
| Douma, S | 2 |
| Verratti, V | 1 |
| Ferrante, C | 1 |
| Soranna, D | 1 |
| Zambon, A | 1 |
| Bhandari, S | 1 |
| Orlando, G | 1 |
| Brunetti, L | 1 |
| Parati, G | 1 |
| Rosner, AK | 1 |
| Closs, EI | 1 |
| Habermeier, A | 1 |
| Gericke, A | 1 |
| Binder, H | 1 |
| Scharrer, I | 1 |
| Pfeiffer, N | 1 |
| Ponto, KA | 1 |
| López, V | 1 |
| Uribe, E | 1 |
| Moraga, FA | 1 |
| de Oliveira Beraldo, D | 1 |
| Rodrigues, CJ | 2 |
| Quinto, BMR | 2 |
| Batista, MC | 3 |
| Charkiewicz, AE | 1 |
| Garley, M | 1 |
| Ratajczak-Wrona, W | 1 |
| Nowak, K | 1 |
| Jabłońska, E | 1 |
| Maślach, D | 1 |
| Omeljaniuk, WJ | 1 |
| Hsu, CN | 15 |
| Hou, CY | 1 |
| Chang-Chien, GP | 1 |
| Lin, S | 1 |
| Chan, JYH | 1 |
| Lee, CT | 5 |
| Tain, YL | 19 |
| Trindade, LR | 1 |
| da Silva, DVT | 1 |
| Baião, DDS | 1 |
| Paschoalin, VMF | 1 |
| Stojanovic, D | 1 |
| Cvetkovic, T | 1 |
| Stojanovic, M | 1 |
| Stefanovic, N | 1 |
| Velickovic-Radovanovic, R | 1 |
| Zivkovic, N | 1 |
| Lin, YJ | 4 |
| Sheen, JM | 1 |
| Lin, IC | 4 |
| Yu, HR | 1 |
| Huang, LT | 14 |
| Salmas, RE | 1 |
| Gulhan, MF | 1 |
| Durdagi, S | 1 |
| Sahna, E | 1 |
| Abdullah, HI | 1 |
| Selamoglu, Z | 1 |
| Triches, CB | 2 |
| Quinto, M | 1 |
| Mayer, S | 2 |
| Batista, M | 1 |
| Zanella, MT | 2 |
| Gavriilaki, E | 1 |
| Dipla, K | 1 |
| Kołakowska, U | 1 |
| Kuroczycka-Saniutycz, E | 1 |
| Olański, W | 1 |
| Wasilewska, A | 1 |
| Chandrasekharan, UM | 1 |
| Wang, Z | 1 |
| Wu, Y | 1 |
| Wilson Tang, WH | 1 |
| Hazen, SL | 1 |
| Wang, S | 3 |
| Elaine Husni, M | 1 |
| Dovinová, I | 1 |
| Hrabárová, E | 1 |
| Jansen, E | 1 |
| Kvandová, M | 1 |
| Majzúnová, M | 1 |
| Berenyiová, A | 1 |
| Barančík, M | 1 |
| Takahashi, K | 3 |
| Ueda, S | 2 |
| Kobayashi, T | 1 |
| Nishiyama, A | 1 |
| Fujisawa, Y | 1 |
| Sugaya, T | 1 |
| Shiota, S | 1 |
| Gohda, T | 1 |
| Horikoshi, S | 1 |
| Suzuki, Y | 1 |
| Hosaf, M | 1 |
| Abusoglu, S | 1 |
| Avci, A | 1 |
| Demir, K | 1 |
| Eryavuz, D | 1 |
| Abusoglu, G | 1 |
| Ding, L | 1 |
| Cheng, P | 1 |
| Wang, L | 2 |
| Hu, J | 1 |
| Zhang, YX | 1 |
| Cai, GW | 1 |
| Huang, GY | 1 |
| Gao, S | 1 |
| Lee, WC | 2 |
| Lin, CY | 4 |
| Bouras, G | 2 |
| Deftereos, S | 1 |
| Tousoulis, D | 3 |
| Giannopoulos, G | 1 |
| Chatzis, G | 1 |
| Tsounis, D | 1 |
| Cleman, MW | 1 |
| Stefanadis, C | 7 |
| Tessari, P | 1 |
| Cecchet, D | 1 |
| Artusi, C | 1 |
| Vettore, M | 1 |
| Millioni, R | 1 |
| Plebani, M | 1 |
| Puricelli, L | 1 |
| Vedovato, M | 1 |
| Taner, A | 2 |
| Kayrak, M | 2 |
| Tekinalp, M | 1 |
| Ayhan, SS | 2 |
| Arıbaş, A | 1 |
| Erdem, SS | 1 |
| Cao, Y | 1 |
| Mu, JJ | 1 |
| Fang, Y | 1 |
| Yuan, ZY | 1 |
| Liu, FQ | 1 |
| Parikh, RV | 1 |
| Scherzer, R | 1 |
| Grunfeld, C | 1 |
| Nitta, EM | 1 |
| Leone, A | 2 |
| Martin, JN | 1 |
| Deeks, SG | 1 |
| Ganz, P | 1 |
| Hsue, PY | 1 |
| Žižek, B | 1 |
| Žižek, D | 1 |
| Bedenčič, K | 1 |
| Jerin, A | 1 |
| Poredoš, P | 1 |
| Han, X | 1 |
| Zhang, DL | 1 |
| Yin, DX | 1 |
| Zhang, QD | 1 |
| Liu, WH | 1 |
| Vasilev, V | 1 |
| Matrozova, J | 1 |
| Elenkova, A | 1 |
| Vandeva, S | 1 |
| Kirilov, G | 1 |
| Zacharieva, S | 1 |
| Klima, Ł | 1 |
| Kawecka-Jaszcz, K | 1 |
| Stolarz-Skrzypek, K | 1 |
| Menne, J | 1 |
| Fijorek, K | 1 |
| Olszanecka, A | 1 |
| Wojciechowska, W | 1 |
| Bilo, G | 1 |
| Czarnecka, D | 1 |
| Chien, SJ | 4 |
| Lin, KM | 1 |
| Kuo, HC | 2 |
| Huang, CF | 2 |
| Cheng, MC | 1 |
| Wu, TH | 1 |
| Cakar, M | 1 |
| Bulucu, F | 1 |
| Karaman, M | 1 |
| Ay, SA | 1 |
| Kurt, Ö | 1 |
| Balta, Ş | 1 |
| Demirkol, S | 1 |
| Sarlak, H | 1 |
| Akhan, M | 1 |
| Altun, B | 1 |
| Yaman, H | 1 |
| Arslan, E | 1 |
| Demirbaş, Ş | 1 |
| Sağlam, K | 2 |
| Yaman, MO | 1 |
| Guner, I | 1 |
| Uzun, H | 2 |
| Sahin, G | 1 |
| Yelmen, N | 1 |
| Fan, NC | 1 |
| Tsai, CM | 2 |
| Han, S | 1 |
| Uludag, MO | 1 |
| Usanmaz, SE | 1 |
| Ayaloglu-Butun, F | 1 |
| Akcali, KC | 1 |
| Demirel-Yilmaz, E | 1 |
| Sasser, JM | 2 |
| Cunningham, MW | 1 |
| Baylis, C | 3 |
| Kurumatani, N | 1 |
| Xia, W | 2 |
| Xu, L | 1 |
| Xu, W | 1 |
| Wang, X | 1 |
| Yao, Y | 1 |
| Notsu, Y | 2 |
| Yano, S | 1 |
| Shibata, H | 1 |
| Nagai, A | 1 |
| Nabika, T | 2 |
| El Shahawy, Y | 1 |
| Soliman, Y | 1 |
| Rifaie, A | 1 |
| Shenawy, H | 1 |
| Behairy, M | 1 |
| Mady, G | 1 |
| Das, UN | 2 |
| Mokhtari, Z | 1 |
| Hosseini, S | 1 |
| Miri, R | 1 |
| Baghestani, AR | 1 |
| Zahedirad, M | 1 |
| Rismanchi, M | 1 |
| Nasrollahzadeh, J | 1 |
| İn, E | 1 |
| Özdemir, C | 1 |
| Kaman, D | 1 |
| Sökücü, SN | 1 |
| Lo, MH | 2 |
| Chen, J | 2 |
| Hamm, LL | 1 |
| Mohler, ER | 1 |
| Hudaihed, A | 1 |
| Arora, R | 1 |
| Chen, CS | 1 |
| Liu, Y | 1 |
| Browne, G | 1 |
| Mills, KT | 1 |
| Kleinpeter, MA | 1 |
| Simon, EE | 1 |
| Rifai, N | 1 |
| Klag, MJ | 1 |
| He, J | 1 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Trevano, FQ | 1 |
| Spaziani, D | 1 |
| Scalise, F | 1 |
| Auguadro, C | 1 |
| Pizzini, P | 1 |
| Tripepi, G | 3 |
| D'Arrigo, G | 1 |
| Mallamaci, F | 2 |
| Mancia, G | 1 |
| Zoccali, C | 5 |
| de Giorgis, T | 1 |
| Marcovecchio, ML | 1 |
| Giannini, C | 1 |
| Chiavaroli, V | 1 |
| Chiarelli, F | 1 |
| Mohn, A | 1 |
| Huang, CC | 1 |
| Leu, HB | 1 |
| Huang, PH | 1 |
| Lin, LY | 1 |
| Wu, TC | 1 |
| Lin, SJ | 1 |
| Chen, JW | 1 |
| Forst, T | 1 |
| Michelson, G | 1 |
| Diessel, S | 1 |
| Jahnke, J | 1 |
| Kapitza, C | 1 |
| Marrocos, MS | 1 |
| Teixeira, AA | 1 |
| Quinto, BM | 1 |
| Carmona, Sde M | 1 |
| Kuniyoshi, M | 1 |
| Dalboni, MA | 1 |
| Manfredi, S | 1 |
| Canziani, ME | 1 |
| Quintana-Villamandos, B | 2 |
| Delgado-Baeza, E | 2 |
| Arnalich-Montiel, A | 1 |
| Arribas, S | 1 |
| Lüneburg, N | 3 |
| Böger, RH | 10 |
| Delgado-Martos, MJ | 1 |
| Fernández-Criado, C | 1 |
| González, MC | 1 |
| Tsai, CC | 1 |
| Mayer-Pickel, K | 1 |
| Kolovetsiou-Kreiner, V | 1 |
| Mörtl, MG | 1 |
| Schlembach, D | 1 |
| Eberhard, K | 1 |
| Obermayer-Pietsch, B | 1 |
| Lang, U | 1 |
| Cervar-Zivkovic, M | 1 |
| Peng, H | 1 |
| Chen, L | 1 |
| Huang, X | 1 |
| Yang, T | 1 |
| Yu, Z | 1 |
| Cheng, G | 1 |
| Zhang, G | 1 |
| Shi, R | 1 |
| Samson, R | 1 |
| Lee, A | 1 |
| Lawless, S | 1 |
| Hsu, R | 1 |
| Sander, G | 1 |
| Grübler, MR | 1 |
| Gaksch, M | 1 |
| Kienreich, K | 1 |
| Verheyen, ND | 1 |
| Schmid, J | 1 |
| Müllner, C | 1 |
| Richtig, G | 1 |
| Scharnagl, H | 1 |
| Trummer, C | 1 |
| Schwetz, V | 1 |
| Meinitzer, A | 1 |
| Pieske, B | 1 |
| März, W | 1 |
| Tomaschitz, A | 1 |
| Pilz, S | 1 |
| Feng, J | 1 |
| Chen, HW | 1 |
| Pi, LJ | 1 |
| Wang, J | 1 |
| Zhan, DQ | 1 |
| Wang, D | 1 |
| Strandgaard, S | 1 |
| Iversen, J | 1 |
| Wilcox, CS | 1 |
| Thomopoulos, C | 5 |
| Tsioufis, C | 6 |
| Dimitriadis, K | 4 |
| Tsiachris, D | 2 |
| Manolis, A | 1 |
| Alchanatis, M | 1 |
| Kallikazaros, I | 1 |
| Matsuoka, H | 3 |
| Imaizumi, T | 3 |
| Pasini, AF | 1 |
| Garbin, U | 1 |
| Stranieri, C | 1 |
| Boccioletti, V | 1 |
| Mozzini, C | 1 |
| Manfro, S | 1 |
| Pasini, A | 1 |
| Cominacini, M | 1 |
| Cominacini, L | 1 |
| Billecke, SS | 1 |
| D'Alecy, LG | 1 |
| Platel, R | 1 |
| Whitesall, SE | 1 |
| Jamerson, KA | 1 |
| Perlman, RL | 1 |
| Gadegbeku, CA | 1 |
| Chirinos, JA | 1 |
| David, R | 1 |
| Bralley, JA | 1 |
| Zea-Díaz, H | 1 |
| Muñoz-Atahualpa, E | 1 |
| Corrales-Medina, F | 1 |
| Cuba-Bustinza, C | 1 |
| Chirinos-Pacheco, J | 1 |
| Medina-Lezama, J | 1 |
| Rufa, A | 1 |
| Blardi, P | 1 |
| De Lalla, A | 1 |
| Cevenini, G | 1 |
| De Stefano, N | 1 |
| Zicari, E | 1 |
| Auteri, A | 1 |
| Federico, A | 1 |
| Dotti, MT | 1 |
| Bokura, H | 1 |
| Suyama, Y | 1 |
| Kobayashi, S | 1 |
| Yamaguchi, S | 1 |
| Masuda, J | 1 |
| Perticone, F | 2 |
| Sciacqua, A | 2 |
| Maio, R | 2 |
| Perticone, M | 2 |
| Galiano Leone, G | 1 |
| Bruni, R | 1 |
| Di Cello, S | 1 |
| Pascale, A | 1 |
| Talarico, G | 1 |
| Greco, L | 1 |
| Andreozzi, F | 1 |
| Sesti, G | 2 |
| Ono, Y | 1 |
| Nakaya, Y | 1 |
| Bando, S | 1 |
| Soeki, T | 1 |
| Ito, S | 1 |
| Sata, M | 1 |
| Guagnano, MT | 1 |
| Ferroni, P | 1 |
| Santilli, F | 1 |
| Paoletti, V | 1 |
| Manigrasso, MR | 1 |
| Pescara, L | 1 |
| Cuccurullo, C | 1 |
| Ciabattoni, G | 1 |
| Davì, G | 1 |
| Cottart, CH | 1 |
| Laguillier, C | 1 |
| Nivet-Antoine, V | 1 |
| Klimczak, C | 1 |
| Sebban, C | 1 |
| Beaudeux, JL | 1 |
| Li, D | 5 |
| Chen, BM | 3 |
| Peng, J | 1 |
| Zhang, YS | 1 |
| Li, XH | 1 |
| Yuan, Q | 1 |
| Hu, CP | 2 |
| Deng, HW | 2 |
| Banday, AA | 1 |
| Lokhandwala, MF | 1 |
| Ngo, DT | 1 |
| Sverdlov, AL | 1 |
| McNeil, JJ | 1 |
| Horowitz, JD | 1 |
| Soldatos, N | 1 |
| Syrseloudis, D | 1 |
| Kasiakogias, A | 2 |
| Silvestros, S | 1 |
| Stefanadi, E | 4 |
| Mostratou, E | 1 |
| Hu, X | 2 |
| Xu, X | 2 |
| Zhu, G | 1 |
| Atzler, D | 3 |
| Kimoto, M | 3 |
| Schwedhelm, E | 5 |
| Zhang, P | 2 |
| Chen, Y | 2 |
| Rodionov, RN | 1 |
| Murry, DJ | 1 |
| Vaulman, SF | 1 |
| Stevens, JW | 1 |
| Lentz, SR | 1 |
| Nishiyama, Y | 1 |
| Ueda, M | 1 |
| Katsura, K | 1 |
| Otsuka, T | 1 |
| Abe, A | 1 |
| Nagayama, H | 1 |
| Katayama, Y | 1 |
| Feng, W | 1 |
| Guan, M | 1 |
| Yu, Y | 1 |
| Li, J | 2 |
| Qu, X | 1 |
| Andrikou, E | 1 |
| Mihas, C | 1 |
| Miliou, A | 3 |
| Papademetriou, V | 2 |
| Bacaksiz, A | 1 |
| Vatankulu, MA | 1 |
| Yazici, M | 1 |
| Ulgen, MS | 1 |
| Chen, GF | 1 |
| Wagner, L | 1 |
| Zharikov, S | 1 |
| Moningka, NC | 1 |
| Sonmez, A | 1 |
| Celebi, G | 1 |
| Erdem, G | 1 |
| Tapan, S | 1 |
| Genc, H | 2 |
| Tasci, I | 1 |
| Ercin, CN | 1 |
| Dogru, T | 1 |
| Kilic, S | 1 |
| Uckaya, G | 1 |
| Yilmaz, MI | 1 |
| Erbil, MK | 1 |
| Kutlu, M | 1 |
| Mihout, F | 1 |
| Shweke, N | 1 |
| Bigé, N | 1 |
| Jouanneau, C | 1 |
| Dussaule, JC | 1 |
| Ronco, P | 1 |
| Chatziantoniou, C | 1 |
| Boffa, JJ | 1 |
| Lau, YT | 4 |
| Głowińska-Olszewska, B | 1 |
| Luczyński, W | 1 |
| Jabłońska, J | 1 |
| Otocka, A | 1 |
| Florys, B | 1 |
| Bossowski, A | 1 |
| Serg, M | 1 |
| Kampus, P | 1 |
| Kals, J | 1 |
| Zagura, M | 1 |
| Muda, P | 1 |
| Tuomainen, TP | 2 |
| Zilmer, K | 1 |
| Salum, E | 1 |
| Zilmer, M | 1 |
| Eha, J | 1 |
| Korandji, C | 1 |
| Zeller, M | 1 |
| Guilland, JC | 1 |
| Collin, B | 1 |
| Lauzier, B | 1 |
| Sicard, P | 1 |
| Duvillard, L | 1 |
| Goirand, F | 1 |
| Moreau, D | 1 |
| Cottin, Y | 1 |
| Rochette, L | 1 |
| Vergely, C | 1 |
| Marín, M | 1 |
| Máñez, S | 1 |
| Repossi, G | 1 |
| Dain, A | 1 |
| Eynard, AR | 1 |
| Yano, Y | 1 |
| Hoshide, S | 1 |
| Tamaki, N | 1 |
| Inokuchi, T | 1 |
| Nagata, M | 1 |
| Yokota, N | 1 |
| Hidaka, T | 1 |
| Kanemaru, Y | 1 |
| Matsuda, S | 1 |
| Kuwabara, M | 1 |
| Shimada, K | 1 |
| Kario, K | 1 |
| Guo, R | 1 |
| Chen, QQ | 1 |
| Chen, X | 1 |
| Antoniades, C | 1 |
| Marinou, K | 1 |
| Papageorgiou, N | 1 |
| Hatzis, G | 1 |
| Guo, H | 1 |
| Lu, Z | 1 |
| Fassett, J | 1 |
| Bache, RJ | 1 |
| Schulz, E | 1 |
| Gori, T | 1 |
| Münzel, T | 1 |
| Moriguchi, Y | 1 |
| Yogo, K | 1 |
| Aizawa, K | 1 |
| Serizawa, K | 1 |
| Tashiro, Y | 1 |
| Yorozu, K | 1 |
| Ishizuka, N | 1 |
| Iwabuchi, S | 1 |
| Kitamura, H | 1 |
| Nishimura, T | 1 |
| Schmidlin, O | 1 |
| Forman, A | 1 |
| Sebastian, A | 1 |
| Morris, RC | 1 |
| Gervasoni, J | 1 |
| Bonelli, F | 1 |
| Zuppi, C | 1 |
| Zappacosta, B | 1 |
| Mordente, A | 1 |
| Calvani, R | 1 |
| Persichilli, S | 1 |
| Makris, T | 1 |
| Michaelides, A | 1 |
| Glyn, MC | 1 |
| Anderssohn, M | 1 |
| Van Rooyen, JM | 1 |
| Schutte, R | 1 |
| Huisman, HW | 1 |
| Fourie, CM | 1 |
| Smith, W | 1 |
| Malan, L | 1 |
| Malan, NT | 1 |
| Mels, CM | 1 |
| Schutte, AE | 1 |
| Aggelis, A | 1 |
| Tzamou, V | 1 |
| Kyvelou, SM | 1 |
| Mikhailidis, DP | 1 |
| Karatzi, K | 1 |
| Stamatelopoulos, K | 1 |
| Lykka, M | 1 |
| Mantzouratou, P | 1 |
| Skalidi, S | 1 |
| Zakopoulos, N | 1 |
| Papamichael, C | 1 |
| Sidossis, LS | 1 |
| Bai, F | 1 |
| Makino, T | 1 |
| Ono, T | 1 |
| Mizukami, H | 1 |
| Khan, BV | 1 |
| Rahman, ST | 1 |
| Haque, T | 1 |
| Merchant, N | 1 |
| Bhaheetharan, S | 1 |
| Harris, J | 1 |
| Umar, K | 1 |
| Wahi, J | 1 |
| Ferdinand, KC | 1 |
| Wei, D | 1 |
| He, WY | 1 |
| Lv, QZ | 1 |
| Ronden, RA | 1 |
| Houben, AJ | 1 |
| Teerlink, T | 2 |
| Bakker, JA | 1 |
| Bierau, J | 1 |
| Stehouwer, CD | 1 |
| De Leeuw, PW | 1 |
| Kroon, AA | 1 |
| Sladowska-Kozłowska, J | 1 |
| Litwin, M | 1 |
| Niemirska, A | 1 |
| Płudowski, P | 1 |
| Wierzbicka, A | 1 |
| Skorupa, E | 1 |
| Wawer, ZT | 1 |
| Janas, R | 1 |
| Parlak, A | 1 |
| Iyisoy, A | 1 |
| Aydogan, U | 1 |
| Cakir, E | 1 |
| Inrig, JK | 1 |
| Van Buren, P | 1 |
| Kim, C | 1 |
| Vongpatanasin, W | 1 |
| Povsic, TJ | 1 |
| Toto, R | 1 |
| Gönenç, A | 1 |
| Hacışevki, A | 1 |
| Tavil, Y | 1 |
| Çengel, A | 1 |
| Torun, M | 1 |
| Sydow, K | 1 |
| Schmitz, C | 1 |
| von Leitner, EC | 1 |
| von Leitner, R | 1 |
| Klinke, A | 1 |
| Krebs, C | 1 |
| Wieboldt, H | 1 |
| Ehmke, H | 1 |
| Meinertz, T | 1 |
| Blankenberg, S | 1 |
| Magnus, T | 1 |
| Baldus, S | 1 |
| Wenzel, U | 1 |
| Jabecka, A | 1 |
| Ast, J | 1 |
| Bogdaski, P | 1 |
| Drozdowski, M | 1 |
| Pawlak-Lemaska, K | 1 |
| Cielewicz, AR | 1 |
| Pupek-Musialik, D | 1 |
| Ozturk, S | 1 |
| Karadag, S | 1 |
| Yegen, M | 1 |
| Gursu, M | 1 |
| Uzun, S | 1 |
| Aydin, Z | 1 |
| Gurdal, A | 1 |
| Koldas, M | 1 |
| Kumbasar, B | 1 |
| Kazancioglu, R | 1 |
| Li, H | 1 |
| Wu, CJ | 1 |
| Li, X | 1 |
| Wang, CX | 1 |
| Ma, JP | 1 |
| Xia, XS | 1 |
| Delles, C | 1 |
| Schneider, MP | 1 |
| John, S | 2 |
| Gekle, M | 1 |
| Schmieder, RE | 2 |
| Osanai, T | 2 |
| Fujiwara, N | 2 |
| Saitoh, M | 1 |
| Sasaki, S | 1 |
| Tomita, H | 1 |
| Nakamura, M | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Okumura, K | 2 |
| Ito, A | 1 |
| Egashira, K | 1 |
| Narishige, T | 1 |
| Muramatsu, K | 1 |
| Takeshita, A | 1 |
| Päivä, H | 1 |
| Laakso, J | 1 |
| Laine, H | 1 |
| Laaksonen, R | 2 |
| Knuuti, J | 1 |
| Raitakari, OT | 1 |
| Holm, T | 1 |
| Aukrust, P | 1 |
| Aagaard, E | 1 |
| Ueland, T | 1 |
| Haugstad, TS | 1 |
| Kjekshus, J | 1 |
| Simonsen, S | 1 |
| Frøland, SS | 1 |
| Gullestad, L | 1 |
| Andreassen, AK | 1 |
| Zhang, WR | 2 |
| Tao, LJ | 2 |
| Kielstein, JT | 3 |
| Bode-Böger, SM | 3 |
| Frölich, JC | 2 |
| Ritz, E | 3 |
| Haller, H | 2 |
| Fliser, D | 2 |
| Achan, V | 1 |
| Broadhead, M | 1 |
| Malaki, M | 1 |
| Whitley, G | 1 |
| Leiper, J | 1 |
| MacAllister, R | 1 |
| Vallance, P | 2 |
| Fleck, C | 1 |
| Schweitzer, F | 1 |
| Karge, E | 1 |
| Busch, M | 1 |
| Stein, G | 1 |
| Saito, Y | 1 |
| Kurabayashi, M | 1 |
| Nakamura, T | 1 |
| Morita, H | 1 |
| Nagai, R | 1 |
| Hirata, Y | 2 |
| Napoli, C | 1 |
| Sica, V | 1 |
| de Nigris, F | 1 |
| Pignalosa, O | 1 |
| Condorelli, M | 1 |
| Ignarro, LJ | 1 |
| Liguori, A | 1 |
| Takiuchi, S | 2 |
| Fujii, H | 2 |
| Kamide, K | 1 |
| Horio, T | 1 |
| Nakatani, S | 1 |
| Hiuge, A | 1 |
| Rakugi, H | 1 |
| Ogihara, T | 1 |
| Kawano, Y | 2 |
| Curgunlu, A | 1 |
| Bavunoğlu, I | 1 |
| Karter, Y | 1 |
| Vehid, S | 1 |
| Xiong, Y | 1 |
| Maas, R | 2 |
| Tsuda, K | 4 |
| Nishio, I | 3 |
| Augustyniak, RA | 1 |
| Thomas, GD | 1 |
| Victor, RG | 1 |
| Zhang, W | 1 |
| Valkonen, VP | 1 |
| Quispe-Bravo, S | 1 |
| Skamira, C | 1 |
| Matsuguma, K | 1 |
| Yamagishi, S | 1 |
| Matsumoto, Y | 1 |
| Kaneyuki, U | 1 |
| Shibata, R | 1 |
| Fujimura, T | 1 |
| Kato, S | 1 |
| Okuda, S | 2 |
| Bellinghieri, G | 1 |
| Santoro, D | 1 |
| Mallamace, A | 1 |
| Di Giorgio, RM | 1 |
| De Luca, G | 1 |
| Savica, V | 1 |
| Wieczorek-Surdacka, E | 1 |
| Surdacki, A | 1 |
| Schubert, B | 1 |
| Sulowicz, W | 1 |
| Xia, K | 2 |
| Zhao, ZY | 1 |
| Li, NS | 1 |
| Luo, D | 1 |
| Jiang, DJ | 2 |
| Zhou, Z | 1 |
| Tan, B | 1 |
| Liu, H | 1 |
| Carlström, M | 1 |
| Brown, RD | 1 |
| Edlund, J | 1 |
| Sällström, J | 1 |
| Larsson, E | 1 |
| Palm, F | 1 |
| Wåhlin, N | 1 |
| Persson, AE | 1 |
| Tomiyama, H | 1 |
| Yamada, J | 1 |
| Koji, Y | 1 |
| Shiina, K | 1 |
| Yoshida, M | 1 |
| Yamashina, A | 1 |
| Fukagawa, M | 1 |
| Galle, J | 1 |
| Pinnetti, S | 1 |
| Wanner, C | 1 |
| Fickling, SA | 1 |
| Williams, D | 1 |
| Nussey, SS | 1 |
| Whitley, GS | 1 |
| Itoh, S | 1 |
| Kohno, K | 1 |
| Tamai, O | 1 |
| Wada, Y | 1 |
| Yasukawa, H | 1 |
| Iwami, G | 1 |
| Goonasekera, CD | 2 |
| Rees, DD | 2 |
| Woolard, P | 1 |
| Frend, A | 1 |
| Shah, V | 2 |
| Dillon, MJ | 2 |
| Sato, J | 1 |
| Masuda, H | 1 |
| Tamaoki, S | 1 |
| Hamasaki, H | 1 |
| Ishizaka, K | 1 |
| Matsubara, O | 1 |
| Azuma, H | 1 |
| Kelly, JJ | 1 |
| Tam, SH | 1 |
| Williamson, PM | 1 |
| Lawson, J | 1 |
| Whitworth, JA | 1 |
| Kamada, T | 1 |
| Katoh, T | 1 |
| Kimura, K | 2 |
| Masuyama, Y | 2 |
| Kinoshita, Y | 1 |
| Leclercq, B | 1 |
| Jaimes, EA | 1 |
| Raij, L | 1 |
| Stühlinger, MC | 1 |
| Abbasi, F | 1 |
| Chu, JW | 1 |
| Lamendola, C | 1 |
| McLaughlin, TL | 1 |
| Cooke, JP | 1 |
| Reaven, GM | 1 |
| Tsao, PS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258] | 102 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Styrian Vitamin D Hypertension Trial: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Systolic Ambulatory Blood Pressure in Vitamin D Deficient Hypertensive Patients[NCT02136771] | Phase 4 | 200 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Effects of Oral Antioxidant Cocktail on Vascular Function and Blood Flow in Cardiovascular Disease Patients[NCT03629613] | 0 participants (Actual) | Interventional | 2020-12-01 | Withdrawn (stopped due to discontinued due to change in operating plans prior to study initiation and enrollment) | |||
| Effect of Tahini Consumption on Oxidative Stress and Inflammation Markers as Well as Endothelial Function and Arterial Stiffness in Patients With Type 2 Diabetes[NCT05396079] | 20 participants (Anticipated) | Interventional | 2023-03-28 | Recruiting | |||
| Effect of Tahini Consumption on Oxidative Stress and Inflammation Markers as Well as Endothelial Function and Arterial Stiffness in Healthy Volunteers[NCT04608747] | 20 participants (Actual) | Interventional | 2020-01-02 | Completed | |||
| Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients[NCT00827775] | Phase 4 | 55 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Pilot Study of the Effect of Dietary Sodium Intake on Assessments of Vascular Endothelium[NCT01550315] | 27 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry~CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry" (NCT00827775)
Timeframe: 12 weeks
| Intervention | % of mononuclear cells (Median) | |
|---|---|---|
| Baseline ALDH bright | Baseline CD34/CD133 endothelial progenitor cells | |
| Control | 0.052 | 0.059 |
"ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry~CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry" (NCT00827775)
Timeframe: 12 weeks
| Intervention | % of mononuclear cells (Median) | |||
|---|---|---|---|---|
| Baseline ALDH bright | Follow up ALDH bright | Baseline CD34/CD133 endothelial progenitor cells | Follow up CD34/CD133 | |
| Intervention | 0.034 | 0.027 | 0.033 | 0.029 |
Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later (NCT00827775)
Timeframe: 12 weeks
| Intervention | % dilation from baseline (Mean) |
|---|---|
| Baseline FMD | |
| Control | 1.67 |
Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later (NCT00827775)
Timeframe: 12 weeks
| Intervention | % dilation from baseline (Mean) | |
|---|---|---|
| Baseline FMD | Follow Up FMD | |
| Intervention | 1.03 | 1.4 |
The primary analysis will involve a non-parametric, paired, Signed Rank test of flow mediated dilation (FMD) between all subjects (POTS & control subjects) on the high sodium diet vs low sodium diet (NCT01550315)
Timeframe: FMD was assessed on the morning of day 7, after 6 days of being on either a high salt diet or a low salt diet.
| Intervention | percentage of change (Mean) |
|---|---|
| High Sodium POTS | 12.75 |
| Low Sodium Diet POTS | 11.65 |
| High Sodium Controls | 11.43 |
| Low Sodium Controls | 12.75 |
27 reviews available for n(g),n(g')-dimethyl-l-arginine and Hypertension
| Article | Year |
|---|---|
Activation of arginase II by asymmetric dimethylarginine and homocysteine in hypertensive rats induced by hypoxia: a new model of nitric oxide synthesis regulation in hypertensive processes?
Topics: Animals; Arginase; Arginine; Disease Models, Animal; Homocysteine; Hypertension; Hypoxia; Nitric Oxi | 2021 |
Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases.
Topics: Antioxidant Response Elements; Antioxidants; Arginine; Cardiotonic Agents; Diabetes Mellitus; Drug C | 2021 |
Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?
Topics: Aging; Amidohydrolases; Arginine; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Ch | 2013 |
Restoration of asymmetric dimethylarginine-nitric oxide balance to prevent the development of hypertension.
Topics: Animals; Arginine; Humans; Hypertension; Nitric Oxide | 2014 |
Nutritional factors in the prevention and management of coronary artery disease and heart failure.
Topics: Alprostadil; Anti-Inflammatory Agents; Arginine; CD59 Antigens; Coronary Artery Disease; Diabetes Me | 2015 |
Targeting on Asymmetric Dimethylarginine-Related Nitric Oxide-Reactive Oxygen Species Imbalance to Reprogram the Development of Hypertension.
Topics: Animals; Arginine; Humans; Hypertension; Kidney; Nitric Oxide; Reactive Oxygen Species | 2016 |
Novel Pathophysiological Mechanisms in Hypertension.
Topics: Animals; Antihypertensive Agents; Arginine; Biomarkers; Blood Pressure; Cytokines; Drug Resistance; | 2017 |
[Pathophysiology of mild hypertension: role of endothelial function].
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2008 |
[Biology of arterial ageing and arteriosclerosis].
Topics: Adult; Aged; Aging; Arginine; Arteriosclerosis; Atherosclerosis; Calcinosis; Diagnostic Techniques, | 2009 |
Pharmacological interventions on asymmetric dimethylarginine, a clinical marker of vascular disease.
Topics: Adrenergic Antagonists; Angiotensins; Arginine; Diabetes Complications; Humans; Hydroxymethylglutary | 2011 |
L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes.
Topics: Animals; Antihypertensive Agents; Arginine; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans | 2011 |
Oxidative stress and endothelial dysfunction in hypertension.
Topics: Animals; Arginine; Endothelium, Vascular; Humans; Hypertension; NADPH Oxidases; Nitric Oxide Synthas | 2011 |
Nitric oxide synthase derangements and hypertension in kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Chronic Disease; Disease Progression; Humans; Hypertension; Kidn | 2012 |
[Cardiovascular events in chronic advanced renal insufficiency. Current concepts].
Topics: Anemia; Arginine; C-Reactive Protein; Cardiovascular Diseases; Humans; Hyperhomocysteinemia; Hyperli | 2003 |
Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia.
Topics: Animals; Arginine; Biological Availability; Cyclic GMP; Endothelium, Vascular; Humans; Hypercholeste | 2003 |
Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases.
Topics: Amino Acids; Arginine; Case-Control Studies; Creatinine; Heart Diseases; Humans; Hypertension; Kidne | 2003 |
Novel cardiovascular risk factors in end-stage renal disease.
Topics: Arginine; Calcinosis; Cardiovascular Diseases; Humans; Hypertension; Inflammation; Kidney Failure, C | 2004 |
Atherosclerosis in dialyzed patients.
Topics: Anemia; Animals; Arginine; Arteriosclerosis; Biomarkers; Cause of Death; Comorbidity; Coronary Arter | 2004 |
[Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data].
Topics: Adult; Aged; Aged, 80 and over; Animals; Arginine; Arteriosclerosis; Biomarkers; Cardiovascular Dise | 2004 |
[Involvement of homocysteine in the pathogenesis of hypertension and hypertensive target-organ damage].
Topics: Arginine; Arteriosclerosis; Biopterins; Cell Division; Endothelium, Vascular; Folic Acid; Homocystei | 2004 |
[NO and hypertension].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Arginine; Arteriosclerosis; Biopterins; C- | 2004 |
Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Cardiovascular Diseases; Carotid Arteries; Carotid S | 2005 |
Nitric oxide pathway as new drug targets for refractory hypertension.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Pressure; Endothelium, Vascular; Humans; Hypertens | 2005 |
DDAH gene and cardiovascular risk.
Topics: Amidohydrolases; Arginine; Cardiovascular Diseases; Humans; Hypertension; Male; Mutation; Polymorphi | 2005 |
L-arginine: a new opportunity in the management of clinical derangements in dialysis patients.
Topics: Adult; Aged; Animals; Arginine; Citrulline; Diabetic Nephropathies; Endothelium, Vascular; Female; H | 2006 |
[Nitric oxide].
Topics: Adiponectin; Aldosterone; Animals; Arginine; Blood Pressure; Cardiovascular Diseases; Endothelium, V | 2006 |
Nitric oxide synthase and hypertension.
Topics: Animals; Arginine; Endothelium, Vascular; Humans; Hypertension; Nitric Oxide Synthase | 2002 |
24 trials available for n(g),n(g')-dimethyl-l-arginine and Hypertension
| Article | Year |
|---|---|
Impact of Intensive Lifestyle Treatment (Diet Plus Exercise) on Endothelial and Vascular Function, Arterial Stiffness and Blood Pressure in Stage 1 Hypertension: Results of the HINTreat Randomized Controlled Trial.
Topics: Adult; Arginine; Blood Pressure; Carotid Intima-Media Thickness; Diet Therapy; Endothelium, Vascular | 2020 |
Role of endothelial function determined by asymmetric dimethylarginine in the prediction of resistant hypertension: A subanalysis of ReHOT trial.
Topics: Antihypertensive Agents; Arginine; Blood Pressure; Humans; Hypertension | 2020 |
Homocysteine and Arginine-to-Asymmetric Dimethylarginine Ratio Associated With Blood Pressure Abnormalities in Children With Early Chronic Kidney Disease.
Topics: Adolescent; Arginine; Blood Pressure; Child; Cross-Sectional Studies; Female; Homocysteine; Humans; | 2015 |
Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease.
Topics: Adult; Aged; Albuminuria; Arginine; Biomarkers; Blood Glucose; Cell Adhesion Molecules; Comorbidity; | 2015 |
Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension.
Topics: Aged; Arginine; Blood Pressure; Drug Resistance; Female; Heart Rate; Humans; Hypertension; Longitudi | 2015 |
Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients.
Topics: Aged; Arginine; Arterial Pressure; C-Reactive Protein; Cyclic GMP; Cystatin C; Dipeptidyl-Peptidase | 2016 |
Effects of Vitamin D3 on asymmetric- and symmetric dimethylarginine in arterial hypertension.
Topics: Aged; Analysis of Variance; Arginine; Blood Pressure; Cholecalciferol; Dietary Supplements; Double-B | 2018 |
Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Amidohydrolases; Antihypertensive Agents; Arginine; Atenolol; Ben | 2008 |
Endothelial dysfunction, ADMA and insulin resistance in essential hypertension.
Topics: Acetylcholine; Adult; Arginine; Case-Control Studies; Endothelium, Vascular; Female; Homeostasis; Hu | 2010 |
Salt sensitivity in blacks: evidence that the initial pressor effect of NaCl involves inhibition of vasodilatation by asymmetrical dimethylarginine.
Topics: Adult; Arginine; Black or African American; Blood Pressure; Dose-Response Relationship, Drug; Female | 2011 |
Sesame oil consumption exerts a beneficial effect on endothelial function in hypertensive men.
Topics: Adult; Analysis of Variance; Arginine; Biomarkers; Blood Pressure; Brachial Artery; Diet; Endotheliu | 2013 |
Sesame oil consumption exerts a beneficial effect on endothelial function in hypertensive men.
Topics: Adult; Analysis of Variance; Arginine; Biomarkers; Blood Pressure; Brachial Artery; Diet; Endotheliu | 2013 |
Sesame oil consumption exerts a beneficial effect on endothelial function in hypertensive men.
Topics: Adult; Analysis of Variance; Arginine; Biomarkers; Blood Pressure; Brachial Artery; Diet; Endotheliu | 2013 |
Sesame oil consumption exerts a beneficial effect on endothelial function in hypertensive men.
Topics: Adult; Analysis of Variance; Arginine; Biomarkers; Blood Pressure; Brachial Artery; Diet; Endotheliu | 2013 |
Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study.
Topics: Adult; Aged; Antihypertensive Agents; Arginine; Benzopyrans; Black or African American; Dose-Respons | 2012 |
Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.
Topics: Aged; Anthracenes; Antihypertensive Agents; Arginine; Blood Pressure; C-Reactive Protein; Case-Contr | 2012 |
Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.
Topics: AC133 Antigen; Adult; Aged; Aldehyde Dehydrogenase; Antigens, CD; Antigens, CD34; Antihypertensive A | 2012 |
Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citruline, L-arginine and antioxidant status.
Topics: Administration, Oral; Adult; Antioxidants; Arginine; Blood Pressure Monitoring, Ambulatory; Citrulli | 2012 |
Organic nitrates favor regression of left ventricular hypertrophy in hypertensive patients on chronic peritoneal dialysis.
Topics: Adult; Aged; Antihypertensive Agents; Arginine; Blood Pressure; Female; Humans; Hypertension; Hypert | 2013 |
[Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients].
Topics: Aged; Antihypertensive Agents; Arginine; Female; Folic Acid; Homocysteine; Humans; Hypertension; Mal | 2012 |
Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension.
Topics: Acrylates; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease.
Topics: Arginine; Blood Pressure; Cardiovascular Diseases; Female; Humans; Hypertension; Kidney Failure, Chr | 2002 |
Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.
Topics: Adult; Amidohydrolases; Arginine; Blood Pressure; Cardiac Output; Double-Blind Method; Heart Rate; H | 2003 |
Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arginine; Captopril; Enalapril; Female; Humans; Hypertensi | 2004 |
[Changes of serum asymmetric dimethylarginine in essential hypertension before and after the treatment].
Topics: Adult; Aged; Antihypertensive Agents; Arginine; Enalapril; Female; Humans; Hypertension; Losartan; M | 2005 |
Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pre | 2008 |
129 other studies available for n(g),n(g')-dimethyl-l-arginine and Hypertension
| Article | Year |
|---|---|
Effect of profilin-1 on the asymmetric dimethylarginine-induced vascular lesion-associated hypertension.
Topics: Animals; Arginine; Cell Proliferation; Endothelium, Vascular; Humans; Hypertension; Myocytes, Smooth | 2022 |
Urinary excretion of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine is positively related to nitric oxide level in tissues of normotensive and hypertensive rats.
Topics: Animals; Arginine; Chromatography, Liquid; Citrulline; Hypertension; Male; Nitric Oxide; Rats; Rats, | 2023 |
Circadian blood pressure variability and asymmetric dimethylarginine in patients with glaucoma: cross-sectional study of The LIGHT cohort.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cross-Sectional Studies; Gl | 2023 |
Assessment of Endothelial Dysfunction with Methylated Arginines and L-arginine in Cadmium-Exposed People: a Pilot Study.
Topics: Adult; Arginine; Atherosclerosis; Cadmium; Chromatography, Liquid; Endothelium, Vascular; Environmen | 2019 |
Effect of high-altitude trekking on blood pressure and on asymmetric dimethylarginine and isoprostane production: Results from a Mount Ararat expedition.
Topics: Altitude; Arginine; Blood Pressure; Expeditions; Humans; Hypertension; Hypoxia; Isoprostanes; Male; | 2020 |
[Asymmetric dimethylarginine (ADMA) in retinal vein occlusion-Results from the Gutenberg RVO study].
Topics: Aged; Arginine; Humans; Hypertension; Retinal Vein Occlusion; Risk Factors | 2021 |
Profile of new vascular damage biomarkers in middle-aged men with arterial hypertension.
Topics: Adult; Arginine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Endothelium, Vascular; F | 2021 |
Maternal resveratrol therapy protected adult rat offspring against hypertension programmed by combined exposures to asymmetric dimethylarginine and trimethylamine-N-oxide.
Topics: Animals; Antioxidants; Arginine; Female; Gastrointestinal Microbiome; Hypertension; Methylamines; Pr | 2021 |
Renalase Assessment With Regard to Kidney Function, Lipid Disturbances, and Endothelial Dysfunction Parameters in Stable Renal Transplant Recipients.
Topics: Adult; Antihypertensive Agents; Arginine; C-Reactive Protein; Case-Control Studies; Cholesterol; Cho | 2017 |
Resveratrol prevents the combined maternal plus postweaning high-fat-diets-induced hypertension in male offspring.
Topics: Animals; Arginine; Blood Pressure; Diet, High-Fat; Female; Hypertension; Male; Maternal Nutritional | 2017 |
Effects of propolis, caffeic acid phenethyl ester, and pollen on renal injury in hypertensive rat: An experimental and theoretical approach.
Topics: Animals; Antioxidants; Arginine; Aryldialkylphosphatase; Binding Sites; Caffeic Acids; Glutathione R | 2017 |
Relation of asymmetrical dimethylarginine levels with renal outcomes in hypertensive patients with and without type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Arginine; Biomarkers; Case-Control Studies; Diabetes Complications; Diabetes Mell | 2018 |
Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes.
Topics: Adult; Arginine; Arterial Pressure; Biomarkers; Case-Control Studies; Essential Hypertension; Female | 2018 |
Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension.
Topics: Aged; Arginine; Brazil; C-Reactive Protein; Cardiovascular Diseases; Diabetes Complications; Diabete | 2018 |
Correlation of Salusin Beta with hs-CRP and ADMA in Hypertensive Children and Adolescents.
Topics: Adolescent; Arginine; C-Reactive Protein; Child; Cohort Studies; Female; Humans; Hypertension; Inter | 2018 |
Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.
Topics: Aged; Arginase; Arginine; Arthritis, Rheumatoid; Biomarkers; Cardiovascular Diseases; Comorbidity; F | 2018 |
ADMA, homocysteine and redox status improvement affected by 7-nitroindazole in spontaneously hypertensive rats.
Topics: Animals; Aorta; Arginine; Biomarkers; Disease Models, Animal; Enzyme Inhibitors; Heart Ventricles; H | 2018 |
Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensins; Animals; Arginine; Cardiovascular Diseases; Deoxyguanosin | 2018 |
Total methylated arginine load as a risk parameter in subjects with masked hypertension.
Topics: Arginine; Biomarkers; Blood Pressure Determination; Female; Humans; Hypertension; Male; Masked Hyper | 2020 |
The protective effects of polysaccharide extract from Xin-Ji-Er-Kang formula on Ang II-induced HUVECs injury, L-NAME-induced hypertension and cardiovascular remodeling in mice.
Topics: Angiotensin II; Animals; Aorta; Arginine; Blood Pressure; Cytokines; Drug Evaluation, Preclinical; D | 2019 |
Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers.
Topics: Animals; Arginine; Blotting, Western; Electron Spin Resonance Spectroscopy; Female; Hypertension; Ki | 2013 |
Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo.
Topics: Adult; Age Factors; Aged; Arginine; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Humans | 2013 |
The value of serum asymmetric dimethylarginine levels for the determination of masked hypertension in patients with diabetes mellitus.
Topics: Adult; Arginine; Biomarkers; Blood Pressure Monitoring, Ambulatory; Chi-Square Distribution; Chromat | 2013 |
Impact of high salt independent of blood pressure on PRMT/ADMA/DDAH pathway in the aorta of Dahl salt-sensitive rats.
Topics: Amidohydrolases; Animals; Antihypertensive Agents; Aorta; Arginine; Blood Pressure; Hydralazine; Hyp | 2013 |
Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals.
Topics: Adult; Arginine; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Endothelium, Vascular | 2013 |
Effect of metabolic abnormalities on endothelial dysfunction in normotensive offspring of subject with hypertension.
Topics: Adiponectin; Adult; Arginine; Biomarkers; Brachial Artery; Case-Control Studies; Disease Progression | 2013 |
Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA.
Topics: Animals; Arginine; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Endothe | 2013 |
Asymmetric dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1(sVCAM-1) as circulating markers for endothelial dysfunction in patients with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Arginine; Biomarkers; Blood Glucose; Blood Pressure; Catechola | 2013 |
Structure and function of large arteries in hypertension in relation to oxidative stress markers.
Topics: Adult; Advanced Oxidation Protein Products; Arginine; Arteries; Biomarkers; Carotid Arteries; Caroti | 2013 |
Two different approaches to restore renal nitric oxide and prevent hypertension in young spontaneously hypertensive rats: l-citrulline and nitrate.
Topics: Animals; Arginine; Citrulline; Dietary Supplements; Hypertension; Male; Nitrates; Nitric Oxide; Rats | 2014 |
Renoprotective effects of melatonin in young spontaneously hypertensive rats with L-NAME.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Amidohydrolases; Animals; Antioxidants; Arginine; Blood Pressure; Deoxy | 2014 |
Asymmetric dimethylarginine and augmentation index in newly diagnosed patients with hypertension.
Topics: Adult; Age Factors; Alcohol Drinking; Aorta; Arginine; Arterial Pressure; Biomarkers; C-Reactive Pro | 2015 |
The effects of acute intermittent hypoxia on cardiovascular parameters in normotensive and chronic hypobaric hypoxia-induced hypertensive rabbits.
Topics: Air Pressure; Animals; Arginine; Blood Pressure; Cardiovascular System; Endothelin-1; Hematocrit; Hy | 2014 |
N-acetylcysteine prevents hypertension via regulation of the ADMA-DDAH pathway in young spontaneously hypertensive rats.
Topics: Acetylcysteine; Amidohydrolases; Animals; Arginine; Blood Pressure; Glutathione; Humans; Hypertensio | 2013 |
Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction.
Topics: Amides; Angiotensin-Converting Enzyme 2; Animals; Animals, Newborn; Arginine; Blood Pressure; Blotti | 2015 |
Melatonin therapy prevents programmed hypertension and nitric oxide deficiency in offspring exposed to maternal caloric restriction.
Topics: Animals; Arginine; Caloric Restriction; Female; Hypertension; In Vitro Techniques; Kidney; Male; Mel | 2014 |
Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats.
Topics: Amidohydrolases; Animals; Arginine; Blood Pressure; Body Weight; Hypertension; Kidney; Lung; Male; M | 2014 |
Resveratrol affects histone 3 lysine 27 methylation of vessels and blood biomarkers in DOCA salt-induced hypertension.
Topics: Animals; Antioxidants; Arginine; Biomarkers; Blood Pressure; Blood Vessels; Desoxycorticosterone Ace | 2015 |
Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Arginine; Arterial Pressure; Dinopro | 2014 |
Asymmetric dimethylarginine attenuates the association of melatonin secretion with night-time blood pressure and dipping in elderly individuals.
Topics: Aged; Aged, 80 and over; Aging; Arginine; Blood Pressure; Body Mass Index; Circadian Rhythm; Cross-S | 2014 |
Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension.
Topics: Arginine; Atherosclerosis; Biomarkers; Blood Pressure; Carotid Artery Diseases; Carotid Artery, Comm | 2015 |
Plasma arginine/ADMA ratio as a sensitive risk marker for atherosclerosis: Shimane CoHRE study.
Topics: Aged; Arginine; Atherosclerosis; Biomarkers; Blood Pressure; Body Mass Index; Carotid Arteries; Caro | 2015 |
Relationship between asymmetric dimethylarginine plasma level and left ventricular mass in hemodialysis patients.
Topics: Adult; Arginine; Female; Glomerular Filtration Rate; Humans; Hypertension; Hypertrophy, Left Ventric | 2015 |
Relationship between Dietary Approaches to Stop Hypertension score and Alternative Healthy Eating Index score with plasma asymmetrical dimethylarginine levels in patients referring for coronary angiography.
Topics: Aged; Arginine; Coronary Angiography; Coronary Disease; Coronary Stenosis; Cross-Sectional Studies; | 2015 |
Heat Shock Proteins, L-Arginine, and Asymmetric Dimethylarginine Levels in Patients With Obstructive Sleep Apnea Syndrome.
Topics: Adult; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Disease Susceptibilit | 2015 |
Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine.
Topics: Adolescent; Adolescent Development; Arginine; Biomarkers; Blood Pressure Monitoring, Ambulatory; Bod | 2016 |
Hypertension subtypes modify metabolic response to thiazide diuretics.
Topics: Adiponectin; Adult; Antihypertensive Agents; Arginine; Asian People; Blood Glucose; China; Cholester | 2016 |
Low urinary citrulline/arginine ratio associated with blood pressure abnormalities and arterial stiffness in childhood chronic kidney disease.
Topics: Adolescent; Arginine; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Citr | 2016 |
Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function.
Topics: Alleles; Apolipoproteins E; Arginine; Demography; Female; Humans; Hypertension; Kidney; Kidney Funct | 2016 |
Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?
Topics: Adrenergic beta-1 Receptor Antagonists; Amidohydrolases; Animals; Antihypertensive Agents; Arginine; | 2016 |
Early regression of coronary artery remodeling with esmolol and DDAH/ADMA pathway in hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Amidohydrolases; Animals; Arginine; Blood Pressure; Coronary | 2016 |
N-Acetylcysteine Prevents Programmed Hypertension in Male Rat Offspring Born to Suramin-Treated Mothers.
Topics: Acetylcysteine; Animals; Arginine; Blood Pressure; Female; Fetal Development; Hydrogen Sulfide; Hype | 2016 |
Endothelin 1, ADMA and SDMA in pregnancies with obstetric and thrombotic antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Arginine; Chronic Disease; Endothelin-1; Endothelium, Vascular; Fe | 2016 |
Vascular peroxidase 1 up regulation by angiotensin II attenuates nitric oxide production through increasing asymmetrical dimethylarginine in HUVECs.
Topics: Amidohydrolases; Angiotensin II; Animals; Aorta; Arginine; Cells, Cultured; Endothelium, Vascular; G | 2016 |
Protective effect of tanshinone IIA against cardiac hypertrophy in spontaneously hypertensive rats through inhibiting the Cys-C/Wnt signaling pathway.
Topics: Abietanes; Animals; Arginine; Cardiomegaly; Cardiovascular Agents; Collagen Type I; Collagen Type I, | 2017 |
Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension.
Topics: Adult; Arginine; Blood Pressure; Buttocks; Endothelium-Dependent Relaxing Factors; Female; Humans; H | 2009 |
Obstructive sleep apnoea syndrome is associated with enhanced sub-clinical inflammation and asymmetric dimethyl-arginine levels in hypertensives.
Topics: Adult; Arginine; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studi | 2009 |
Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.
Topics: Adult; Arginine; Biomarkers; Case-Control Studies; Erythrocytes; Female; Humans; Hypertension; Kidne | 2009 |
Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Blood Flow Velocity; Blood Pressure; Carotid Artery D | 2008 |
Plasma levels of asymmetric dimethylarginine in cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy.
Topics: Adult; Antihypertensive Agents; Arginine; Biomarkers; Brain; CADASIL; Chromatography, High Pressure | 2008 |
Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage.
Topics: Arginine; Arteriosclerosis; Biomarkers; Blood Pressure; Brain Damage, Chronic; Cerebral Infarction; | 2009 |
Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzo | 2009 |
Determinants of platelet activation in hypertensives with microalbuminuria.
Topics: Aged; Albuminuria; Arginine; Biomarkers; Disease Progression; Endothelium; Female; Humans; Hypertens | 2009 |
Role of anandamide transporter in regulating calcitonin gene-related peptide production and blood pressure in hypertension.
Topics: Animals; Arachidonic Acids; Arginine; Base Sequence; Blood Pressure; Calcitonin Gene-Related Peptide | 2009 |
Inhibition of natriuretic factors increases blood pressure in rats.
Topics: Amidohydrolases; Animals; Antioxidants; Arginine; Blood Pressure; Buthionine Sulfoximine; Cyclic N-O | 2009 |
Correlates of arterial stiffness in an ageing population: role of asymmetric dimethylarginine.
Topics: Aged; Aging; Arginine; Endothelium, Vascular; Female; Humans; Hypertension; Male; Middle Aged; Risk | 2009 |
The conjoint detrimental effect of chronic periodontal disease and systemic inflammation on asymmetric dimethyl-arginine in untreated hypertensive subjects.
Topics: Arginine; Chronic Disease; Cross-Sectional Studies; Female; Humans; Hypertension; Inflammation; Male | 2010 |
Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine.
Topics: Acetylcholine; Amidohydrolases; Animals; Aorta; Arginine; Brain; Cholinergic Agents; Endothelium, Va | 2009 |
Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production.
Topics: Adenoviridae; Animals; Arginine; Atherosclerosis; Chlorocebus aethiops; Citrulline; COS Cells; Diabe | 2010 |
Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke.
Topics: Age Factors; Aged; Arginine; Biomarkers; Blood Glucose; Brain Ischemia; Cholesterol, LDL; Dyslipidem | 2010 |
Increased levels of asymmetric dimethylarginine and C-reactive protein are associated with impaired vascular reactivity in essential hypertension.
Topics: Adult; Aged; Arginine; Blood Flow Velocity; Brachial Artery; C-Reactive Protein; Female; Humans; Hyp | 2010 |
ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study.
Topics: Adult; Albuminuria; Arginine; Blood Pressure; C-Reactive Protein; Creatinine; Cross-Sectional Studie | 2010 |
Association between exaggerated blood pressure response to exercise and serum asymmetric dimethylarginine levels.
Topics: Adult; Arginine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Cas | 2010 |
Effects of angiotensin type 1 receptor blockade on arginine and ADMA synthesis and metabolic pathways in fawn-hooded hypertensive rats.
Topics: Amidohydrolases; Angiotensin II Type 1 Receptor Blockers; Animals; Arginine; Biphenyl Compounds; Cit | 2010 |
Plasma apelin and ADMA Levels in patients with essential hypertension.
Topics: Adult; Apelin; Arginine; Biomarkers; Blood Pressure; Body Mass Index; Case-Control Studies; Endothel | 2010 |
Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.
Topics: Animals; Arginine; Collagen; Endothelin-1; Enzyme Inhibitors; Fibrosis; Gene Expression Regulation; | 2011 |
Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats.
Topics: Analysis of Variance; Animals; Arginine; Blood Pressure; Blotting, Western; Body Weight; Citrulline; | 2010 |
[Asymmetric dimethylarginine (ADMA) in children with diabetes type 1].
Topics: Adolescent; Adult; Arginine; Biomarkers; Child; Comorbidity; Diabetes Mellitus, Type 1; Endothelium, | 2010 |
Association between asymmetric dimethylarginine and indices of vascular function in patients with essential hypertension.
Topics: Adult; Arginine; Cardiovascular System; Endothelium, Vascular; Female; Hemodynamics; Humans; Hyperte | 2011 |
Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome.
Topics: Animals; Aorta; Arginine; Blood Glucose; Blood Pressure; Body Weight; Disease Models, Animal; Dose-R | 2011 |
Regional differences in hypertensive cardiovascular remodeling between fishing and farming communities in Japan.
Topics: Aged; Agriculture; Arginine; Carotid Arteries; Cross-Sectional Studies; Docosahexaenoic Acids; Eicos | 2011 |
Increased plasma level of asymmetric dimethylarginine in hypertensive rats facilitates platelet aggregation: role of plasma tissue factor.
Topics: Animals; Arginine; Hypertension; Male; Platelet Aggregation; Random Allocation; Rats; Rats, Inbred W | 2011 |
Methionine-induced homocysteinemia impairs endothelial function in hypertensives: the role of asymmetrical dimethylarginine and antioxidant vitamins.
Topics: Adult; Antioxidants; Arginine; Ascorbic Acid; Endothelium, Vascular; Female; Homocysteine; Humans; H | 2011 |
Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
Topics: Amidohydrolases; Animals; Arginine; Blood Pressure; Cardiovascular Diseases; Cells, Cultured; Endoth | 2011 |
Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats.
Topics: Animals; Arginine; Creatinine; Disease Models, Animal; Fibrosis; Hypertension; Hypertrophy, Left Ven | 2011 |
Determination of asymmetric dimethyl arginine in human serum by liquid chromatography-tandem mass spectrometry: clinical application in hypertensive subjects.
Topics: Adolescent; Adult; Arginine; Chromatography, High Pressure Liquid; Female; Humans; Hydrophobic and H | 2011 |
Aliskiren prevents hypertension and reduces asymmetric dimethylarginine in young spontaneously hypertensive rats.
Topics: Amides; Animals; Antihypertensive Agents; Arginine; Blood Pressure; Dose-Response Relationship, Drug | 2011 |
Exercise blood pressure response is related to asymmetric dimethylarginine and osteoprotegerin in hypertension.
Topics: Adult; Arginine; Biomarkers; Blood Pressure; Exercise; Exercise Test; Humans; Hypertension; Male; Mi | 2011 |
Apocynin attenuates oxidative stress and hypertension in young spontaneously hypertensive rats independent of ADMA/NO pathway.
Topics: Acetophenones; Animals; Antioxidants; Arginine; Hypertension; Male; NADPH Oxidases; Nitric Oxide; Ox | 2012 |
Ethnicity-specific differences in L-arginine status in South African men.
Topics: Adult; Aged; Arginine; Black People; Cardiovascular Diseases; Cross-Sectional Studies; Humans; Hyper | 2012 |
Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction.
Topics: Adult; Albuminuria; Arginine; Blood Pressure; Cross-Sectional Studies; Echocardiography; Endothelium | 2011 |
The combined ratios of L-arginine and asymmetric and symmetric dimethylarginine as biomarkers in spontaneously hypertensive rats.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Blood Pressure; Hypertension; Male; Models, Animal; | 2012 |
Anti-hypertensive effects of shichimotsukokato in 5/6 nephrectomized Wistar rats mediated by the DDAH-ADMA-NO pathway.
Topics: Amidohydrolases; Animals; Antihypertensive Agents; Arginine; Hypertension; Nephrectomy; Nitric Oxide | 2012 |
Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency.
Topics: Adult; Aged; Arginine; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Kidney Func | 2012 |
Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy.
Topics: Adiposity; Adolescent; Albuminuria; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; A | 2012 |
The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Arginine; Benzopyrans; C-Reactive Protein; Ethanolamines; Female; Hu | 2012 |
Oxidative stress in patients with essential hypertension: a comparison of dippers and non-dippers.
Topics: Antioxidants; Arginine; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian | 2013 |
Dimethylarginine dimethylaminohydrolase1 is an organ-specific mediator of end organ damage in a murine model of hypertension.
Topics: Amidohydrolases; Animals; Arginine; Blood Pressure; Heart; Humans; Hypertension; Kidney; Male; Mice; | 2012 |
The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients.
Topics: Adolescent; Aged; Arginine; Aspirin; Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studi | 2013 |
Aminoguanidine attenuates hypertension, whereas 7-nitroindazole exacerbates kidney damage in spontaneously hypertensive rats: the role of nitric oxide.
Topics: Amidohydrolases; Animals; Arginine; Blood Pressure; Citrulline; Guanidines; Hypertension; Indazoles; | 2013 |
Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Arginine; Cross-Over Studies; Diabetes Mellitus, Typ | 2002 |
Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia.
Topics: Adult; Age Factors; Arginine; Biomarkers; Blood Flow Velocity; Case-Control Studies; Coronary Circul | 2002 |
Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension.
Topics: Arginine; Blood Pressure; Female; Heart Transplantation; Humans; Hypertension; Inflammation; Male; M | 2002 |
[Relationship between serum asymmetric dimethylarginine and blood pressure in patients with chronic renal failure].
Topics: Adult; Arginine; Chromatography, High Pressure Liquid; Female; Humans; Hypertension; Kidney Failure, | 2002 |
Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects.
Topics: Adult; Aged; Aging; Arginine; Blood Pressure; Female; Glomerular Filtration Rate; Hemodynamics; Huma | 2003 |
Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients.
Topics: Aged; Arginine; Coronary Circulation; Echocardiography, Doppler; Endothelium, Vascular; Female; Fore | 2004 |
Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension.
Topics: Adult; Arginine; Blood Pressure Monitoring, Ambulatory; Case-Control Studies; Endothelium, Vascular; | 2005 |
Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension.
Topics: Acetylcholine; Arginine; Blood Pressure Determination; Case-Control Studies; Chromatography, High Pr | 2005 |
An association between plasma asymmetric dimethylarginine and membrane fluidity of erythrocytes in hypertensive and normotensive men: an electron paramagnetic resonance investigation.
Topics: Arginine; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Humans; Hypertension; Male; Me | 2005 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ar | 2005 |
Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
Topics: Adenoviridae; Amidohydrolases; Animals; Arginine; Cholesterol; Hypertension; Kidney; Kidney Failure, | 2006 |
Elevated plasma asymmetric dimethyl-L-arginine in a patient with Gordon syndrome.
Topics: Arginine; Diagnosis, Differential; Electrolytes; Female; Humans; Hyperkalemia; Hypertension; Middle | 2007 |
[Effect of asymmetric dimethylarginine on platelet-aggregation and losartan intervention in spontaneous hypertensive rat models].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arginine; Hypertension; L | 2006 |
Asymmetric dimethylarginine and hypertension in cerebral small vessel disease.
Topics: Arginine; Blood Pressure; Cerebrovascular Disorders; Enzyme Inhibitors; Humans; Hypertension; Leukoa | 2007 |
Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats.
Topics: Animals; Arginine; Blood Pressure; Hypertension; Losartan; Male; Nitric Oxide; Rats; Rats, Inbred SH | 2007 |
Reduction of NO- and EDHF-mediated vasodilatation in hypertension: role of asymmetric dimethylarginine.
Topics: Animals; Arginine; Biological Factors; Cell Culture Techniques; Down-Regulation; Epoprostenol; Femal | 2007 |
Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals.
Topics: Animals; Arginine; Blood Pressure; Disease Models, Animal; Diuresis; Enzyme Inhibitors; Hydronephros | 2008 |
Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients.
Topics: Aged; Arginine; Carotid Arteries; Echocardiography; Female; Glomerular Filtration Rate; Heart Diseas | 2008 |
Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia.
Topics: Animals; Arginine; Female; Humans; Hypertension; Nitric Oxide; Pre-Eclampsia; Pregnancy; Pregnancy C | 1993 |
Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension.
Topics: Amidohydrolases; Animals; Arginine; Blood Pressure; Hydrolases; Hypertension; Kidney; Nitric Oxide S | 1997 |
Nitric oxide synthase inhibitors and hypertension in children and adolescents.
Topics: Adolescent; Animals; Arginine; Child; Endothelium, Vascular; Enzyme Inhibitors; Female; Glomerular F | 1997 |
Endogenous asymmetrical dimethylarginine and hypertension associated with puromycin nephrosis in the rat.
Topics: Animals; Arginine; Blood Pressure; Body Weight; Cyclic GMP; Endothelium; Glomerulosclerosis, Focal S | 1998 |
The nitric oxide system and cortisol-induced hypertension in humans.
Topics: Arginine; Humans; Hydrocortisone; Hypertension; Male; Nitrates; Nitric Oxide; Nitric Oxide Synthase; | 1998 |
Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension : modulation of nitric oxide synthesis by salt intake.
Topics: Adult; Aged; Arginine; Blood Pressure; Electrolytes; Female; Humans; Hypertension; Lipids; Male; Mid | 2000 |
Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma?
Topics: Adolescent; Adult; Arginine; Arteriosclerosis; Child; Child, Preschool; Endothelium, Vascular; Femal | 2000 |
Nitric oxide improves membrane fluidity of erythrocytes in essential hypertension: An electron paramagnetic resonance investigation.
Topics: Arginine; Blood Pressure; Calcimycin; Cell Membrane; Cyclic GMP; Cyclic N-Oxides; Electron Spin Reso | 2000 |
Electron paramagnetic resonance investigation on modulatory effect of 17beta-estradiol on membrane fluidity of erythrocytes in postmenopausal women.
Topics: Aged; Arginine; Cyclic GMP; Electron Spin Resonance Spectroscopy; Erythrocytes; Estradiol; Female; H | 2001 |
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
Topics: Adult; Arginine; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hy | 2002 |
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; | 2002 |